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 ACE -  Angiotensin Converting Enzyme 
 ACTH - Adrenocorticotrophic Hormone 
AGT -  Angiotensinogen 
ANG I - Angiotensin I 
ANG II - Angiotensin II 
ANOVA - Analysis of Variants 
AT1 -  Angiotensin Type I Receptor  
AT2 -  Angiotensin Type II Receptor  
B 
BP -  Blood Pressure 
BSA -  Bovine Serum Albumin 
C 
 cAMP- Cyclic Adenosine Monophosphate    
 CCD -   Cortical Collecting Duct 
 CD -  Collecting Duct 
CInu -  Clearance of Inulin 
CNS -  Central Nervous System 
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D 
DCT -  Distal Convoluted Tubule 
DMSO - Dimethyl Sulfoxide 
DOCA - Deoxycorticosterone Acetate 
 DTT-  1,4-dithiothreitol 
E 
ECF -  Extracellular Fluid 
ECV -   Extracellular Volume 
ELISA - Enzyme-Linked Immunosorbent Assay 
ENa -  Sodium Excretion 
ENaC - Epithelial Sodium Channel 
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F 
 FENa -  Fractional Excretion of Sodium  
 FEK -  Fractional Excretion of Potassium   
 FELi -  Fractional Excretion of Lithium 
 FF -  Filtration Fraction 
 FITC-  Fluorescein isothiocyanate 
G 
 GFR -  Glomerular Filtration Rate  
H 
 H2O2 -  Hydrogen Peroxide 
HRP-  Horseradish Peroxidase 
I 
 I3C-  Indole 3 Carbinol  
 ICF -  Intracellular Fluid 
IMCD - Inner Medullary Collecting Duct 
I.P. -  Intraperitoneal 
 I.V. -  Intravenous 
K 
 Kb -  Kilobases 
M  
 MABP - Mean Arterial Blood Pressure 
 MD-  Macula Densa 
 MR -  Mineralocorticoid Receptor 
N 
 Na-K-ATPase - Sodium Potassium Pump  
 NCC -  Sodium Chloride Symporter 
Nedd - Neuronal precursor cell Expressed Developmentally Down-
regulated 
NHE- Sodium Hydrogen Exchanger 
 NKCC - Sodium Potassium Chloride Symporter 




 PA -  Primary Aldosteronism 
 PAH -  p-Aminohippuric Acid 
 PInu -  Plasma concentration of Inulin 
 PPAH -  Plasma concentration of p-Aminohippuric Acid 
 PMSF - Phenylmethylsulfonyl Fluoride monohydrate 
 PNa -  Plasma Sodium Concentration 
 ppm -  parts per million 
 PRA -  Plasma Renin Activity 
 PVDF - Polyvinylidene Difluoride 
R 
RAAS - Renin Angiotensin Aldosterone System 
 RBF -  Renal Blood Flow 
 ROMK - Renal Outer Medullary Potassium (K) channel 
 RPF -  Renal Plasma Flow 
 RVR -  Renal Vascular Resistance 
S 
SBP -  Systolic Blood Pressure 
SGK-  Serum- and Glucocorticoid-inducible protein Kinase 
SHR -  Spontaneously Hypertensive Rat 
T 
 TAL-  Thick Ascending Limb  
 TCA -  Trichloroacetic Acid  
U 
UInu -  Urinary Inulin concentration 
UPAH -  Urinary p-Aminohippuric Acid concentration  
 
V 
 VSMC - Vascular Smooth Muscle Cell 
W 
 WNK -  With no lysine (K) 
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Inappropriate modulation of the renin angiotensin system (RAS) can lead to 
derangements of blood pressure homeostasis in humans. Cyp1a1-mRen2.F 
transgenic rats were used to define the renal mechanisms underlying the development 
of angiotensin II-dependent hypertension. These transgenic rats were previously 
generated by introducing the mouse Ren2 gene into the rat genome under the control 
of a Cyp1a1 inducible promoter. The aim of the current investigation was to establish 
the contribution of renal function to the development of hypertension in the Cyp1a1-
mRen2.F transgenic rat. 
 
Expression of the mRen2 transgene was induced by daily gavage of indole 3 carbinol 
(I3C) at the dose of 100mg/kg. Blood pressure was measured in conscious rats after 
1, 3 or 7 days of treatment. The control group received the vegetable oil carrier for 7 
days. In addition blood pressure, renal haemodynamics and excretory function were 
measured under thiobutabarbital anaesthesia.  
 
Transgene induction caused a progressive increase in blood pressure in a time 
dependent manner. Neither glomerular filtration rate nor renal blood flow was 
affected. This indicates proper function of renal autoregulation during the 
experimental time course. Tubular sodium reabsorption was significantly increased 
after the first day of transgene induction and this effect was sustained for the duration 
of treatment. A pharmacological approach was used to localize the increased 
reabsorption to a specific region of the nephron and was found to reflect increased 
activity of the thiazide-sensitive cotransporter (NCC). Chronic administration of 
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thiazide significantly blunted the hypertensive response to transgene induction. 
Similarly AT1 receptor blockade attenuated the hypertensive phenotype and 
prevented the transgene-induced stimulation of NCC activity. In contrast, 
mineralocorticoid receptor blockade did not prevent the development of either 
hypertension or increased NCC activity. 
 
The current study suggests that the development of angiotensin II-dependent 
hypertension is mediated by increased tubular sodium reabsorption. Increased 
activity of NCC is a key hypertensive mechanism in this model and results directly 
from the actions of angiotensin II at the AT1 receptor; indirect aldosterone pathways 











































Hypertension or high blood pressure is a condition in which the blood pressure is 
chronically elevated and remains greater than the accepted upper range of normal 
blood pressure. According to British Hypertension Society guidelines, blood pressure 
below 120mmHg systolic and 80 mmHg diastolic is considered optimal. Blood 
pressure between 120/80mmHg and 139/89mmHg is termed prehypertension and a 
blood pressure of 140/90mmHg or over is called hypertension (Williams et al., 
2004). Hypertension can be subdivided into primary hypertension and secondary 
hypertension. Primary or essential hypertension is a condition in which the cause is 
undetermined or unknown. This accounts for 90-95% of all cases of high blood 
pressure. Secondary hypertension is high blood pressure that results from a 
underlying known and often curable cause such as kidney disease, adrenal disorders, 
thyroid disorders, oral contraceptives, alcohol, amongst others.  
 
Hypertension is one of the main modifiable risk factor for cardiovascular disease, 
ischaemic heart disease and renal diseases (Whitworth et al., 2003). As such, it 
represents a leading cause of mortality and affects approximately 20% to 30% of the 
world’s population. Furthermore, by 2025 it is predicted that 60% of the total 
population will be affected by hypertension (Kearney et al., 2005). The prevalence of 
hypertension in UK has been reported to be approximately 42% in the population 
aged from 35 to 64 (Wolf-Maier et al., 2003). Hypertension is estimated to cause 
~4.5% of global disease burden and is equally widespread in both the developed and 
developing world (Lawes et al., 2008). Thus hypertension is an important global 
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public health challenge and the therapeutic management of high blood pressure 
represents a major economic burden in most countries.  
 
Better management of hypertension can reduce the risk of stroke by 40% and the risk 
of myocardial infarction by 15% (Collins et al., 1990).  Improved hypertension 
management reduces the prevalence of cardiovascular disease but in a significant 
proportion of individuals it is inadequately managed (Chobanian, 2009). With 
current poor hypertension control rates worldwide, more individuals are being 
referred for resistant or refractory hypertension. Thus a better understanding of the 
genesis of hypertension would ultimately aid in the development of targeted 
therapeutics for the treatment of hypertension. 
 
1.1.1 Pathogenesis of hypertension  
 
In simple terms, hypertension can be caused either by increased blood volume 
(volume expansion) or by a reduction in the capacitance of the cardiovascular system 
(Navar, 1997). The kidney plays a major role in hypertension induced by volume 
expansion. In this setting, the kidneys fail to respond adequately to increased 
intravascular volume or have an impaired excretory capacity causing sodium and 
fluid retention (de Wardener, 1990, Hamlyn et al., 1986). In either case, sustained 
volume expansion in-turn increases cardiac output, leading to an over perfusion of 
tissues. The autoregulatory resistance from over perfused tissues then leads to an 
increase in peripheral resistance. This contributes further to increase in total 
resistance and causes hypertension (Coleman & Guyton, 1969, Cowley, 1992). That 
impaired renal natriuretic ability is key for the development of hypertension is 
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supported by both clinical and experimental data (Woolfson & Wardener, 1996). In 
patients with essential hypertension, for example, renal sodium excretion is markedly 
attenuated in response to intravenous saline load. The sodium retention is associated 
with an impairment of pressure natriuresis (Manunta et al., 1999). Kidney cross-
transplantation studies have provided strong evidence in support of the kidney’s 
pivotal role in essential hypertension. Normalization in blood pressure was observed 
in hypertensive patients following bilateral nephrectomy and kidney transplants from 
normotensive donors (Curtis et al., 1983). The incidence of hypertension in 
transplant recipients depends on the familial incidence of hypertension in the donor’s 
family (Guidi et al., 1996). In experimental animals, several kidney cross-
transplantation studies have also showed that normotensive recipient rats develop 
hypertension following a renal graft from genetically hypertensive donor rats 
(Bianchi et al., 1975, Heller et al., 1993, Rettig et al., 1989). Thus the pathogenesis 
of hypertension is primarily controlled by the kidney.  
 
Hypertension can also be caused by increased peripheral resistance or decreased 
cardiovascular capacitance. This can be caused by excess secretion of 
vasoconstrictors such as ANG ΙΙ (Ashton, 2007; Mitchell et al., 1992). Again over-
activation of sympathetic nerves also causes hypertension through this mechanism 
(Julius & Nesbitt, 1996). However, the Guyton Hypothesis (Guyton, 1991) would 
predict that increased blood pressure caused by either mechanism cannot be 
sustained if the pressure natriuresis response is normal: increased blood pressure 
would promote excretion of sodium and reduction in blood volume until arterial 
pressure returned completely to the original set point. However, some 
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vasoconstrictors can also cause renal sodium retention, leading to a profound 
hypertensinogenic stimulus. For example, abnormal activation of the RAAS causes 
an ANG II-dependent vasoconstriction, increasing total peripheral resistance. In 
addition, both ANG II and aldosterone promote sodium retention. The dampening of 
the pressure natriuresis response is synergistic to the vasoconstriction and produces a 
powerful hypertensinogenic stimulus (Mitchell et al., 1992). 
 
Although it is well established that the kidney plays a key role in the pathogenesis of 
hypertension, there is evidence that hypertension can occur independently of the 
kidney. Vascular smooth muscle cell dysfunction may contribute to the pathogenesis 
of hypertension by impacting peripheral resistance without direct participation of the 
kidney (Tang et al., 2003). Several reports indicate that defects in ion channel 
function or dysregulation in the signaling pathway may cause chronic blood pressure 
elevation (Brenner et al., 2000, Zhu et al., 2002).  
 
1.1.2 Genetic components for hypertension 
 
There is substantial evidence that genetic factors contribute to blood pressure and 
hypertension. The normal distribution of blood pressure in the general population 
suggests a complex interaction between environmental and genetic factors. Twin and 
family aggregation studies also indicate the presence of a genetic component 
(Carretero & Oparil, 2000, Luft, 2001). In fact approximately 30% of blood pressure 
variation is attributed to genetic factors (Beevers et al., 2001). Population studies 
demonstrate greater similarity of blood pressure within families than between 
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families (Havlik et al., 1979, Longini et al., 1984). In individuals who have one or 
two hypertensive parents, hypertension is twice as common as in the general 
population. Moreover twin studies suggest that blood pressure is more closely 
correlated in monozygotic than dizygotic twins (Carretero & Oparil, 2000, Luft 
2001). This familial aggregation of blood pressure is not simply due to 
environmental factors. According to the Montreal Adoption Study, blood pressure is 
more closely correlated among biological siblings than adoptive siblings living in the 
same household (Mongeau et al., 1986). 
 
Genetic studies have identified a number of gene mutations which have a large effect 
on blood pressure. These rare monogenic forms of hypertension and hypotension are 
all associated with major defects in renal salt handling (Lifton, 1996). More recently, 
it has been shown that minor variations in these genes are associated with blood 
pressure variability in the general population and thus may contribute to the genesis 
of essential hypertension (Lifton et al., 2001). There have been several genome wide 
association studies (GWAS) attempting to identify candidate genes for hypertension. 
The Wellcome Trust Case Control Consortium (WTCCC) conducted a GWAS for 
seven complex diseases of major public health burden, including hypertension 
(Wellcome Trust Case Control Consortium, 2007). However this study failed to 
identify any Single Nucleotide Polymorphism (SNP) associated with hypertension. 
Moreover there was no evidence for previously identified variants linking with 
hypertension. Two recent studies, Global Blood Pressure Genetics (Global BPgen) 
and Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
have produced more promising results. Global BPgen identified 8 loci associated 
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with blood pressure (Newton-Cheh et al., 2009). CHARGE identified multiple loci 
association with levels of systolic and diastolic blood pressure and hypertension 
(Levy et al., 2009). Joint analysis of results from the two consortia identified 11 
genome-wide significant associations (Hastie et al., 2010; Newton-Cheh et al., 2009; 
Levy et al., 2009). Despite this, GWAS have failed to find strong associations 
between hypertension and specific genes, suggesting that there is no single locus 
responsible for substantial effects on blood pressure. This suggests that directed 
investigation of pathways such as the RAS, which are known to be involved in the 
regulation of blood pressure, may be more beneficial than the identification of 
multiple loci which impart very small effects on blood pressure in the population.  
 
1.2 Renin angiotensin aldosterone system 
 
The renin angiotensin aldosterone system (RAAS) plays an important role in blood 
pressure regulation and fluid homeostasis. It also plays a vital role in the 
pathophysiology of several diseases such as hypertension, cardiac hypertrophy, 
myocardial infarction and various progressive renal diseases. The evidence for this 
comes from genetic studies, identifying associations between angiotensinogen gene 
variants and hypertension in several European and Japanese population studies 
(Jeunemaitre et al., 1992, Hata et al., 1994). Evidence for a renin intronic 
dimorphism and essential hypertension has been reported in the United Arab 
Emirates population (Ahmad et al., 2005). The level of plasma and intracellular ACE 
is modulated by common insertion/deletion polymorphisms of the gene (Soubrier & 
Cambien, 1994, Cox et al., 2002). Marginal significance has been reported between 
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blood pressure and insertion/deletion polymorphisms from two large population-
based studies and this linkage was restricted to males only (Fornage et al., 1998, 
O’Donnell et al., 1998). Furthermore the Framingham Heart Study found strong 
evidence for a quantitative trait locus on chromosome 17, close to the ACE gene 
(Levy et al., 2000). An association between angiotensin receptor variants and 
hypertension was reported in a study performed on a Finnish population (Kainulainen 
et al., 1999), but no association was observed in African Americans (Bonnardeaux et 
al., 1994, Gainer et al., 1997). Pharmacological evidence also supports a role of the 
RAS in essential hypertension: renin inhibitors, ACE inhibitors and AT1 receptor 
antagonists are effective anti-hypertensive agents, even when overt signs of RAS 
activation are lacking (Ibrahim, 2006, Dzau et al., 2001, Pinto & Gradman, 2009).  
 
In brief, the first step of the classical RAS is the cleavage of angiotensinogen, 
secreted from liver, by the enzyme renin, released from juxtaglomerular cells of the 
kidney, to produce angiotensin Ι (ANG Ι). This inactive intermediate is then further 
processed by a metalloprotease produced from the lung, angiotensin-converting 
enzyme (ACE), to produce the major effector of the RAS, angiotensin ΙΙ (ANG ΙΙ). 
Upon binding with its receptor (AT1) ANG ΙΙ directly exerts its physiological effect 
such as blood pressure regulation. ANG ΙΙ also regulates blood pressure indirectly by 
inducing aldosterone synthesis from adrenal cortex. A schematic diagram of the 







Plasma angiotensinogen is the circulating protein substrate for renin in all species. 
The primary site for angiotensinogen synthesis is the liver, from where it is secreted 
constitutively (Li and Brasier, 1996). Angiotensinogen is also expressed, albeit at 
lower levels, in the central nervous system, kidney, heart 
 
 





and adrenal gland (Griendling et al., 1993). No other function of angiotensinogen has 
been reported other than as a precursor of ANG ΙΙ. Angiotensinogen synthesis is 
markedly elevated in response to stress such as tissue injury (Morgan et al., 1996). It 
is also stimulated by hormones such as glococorticoids, thyroid hormones and 
androgens (Morgan et al., 1996). ANG ΙΙ stimulates the hepatic production of 
angiotensinogen by a positive feed back loop (Blair-West et al., 1974; Jaramillo et 
al., 1987, Nasjletti & Masson, 1973). Conversely renin inhibits angiotensinogen 




Renin is a very specific protease which catalyzes the cleavage of angiotensinogen to 
ANG Ι. Renin is secreted from specialized cells of the afferent arterioles called 
juxtaglomerular (JG) cells (Griendling, et al., 1993, Hackenthal et al., 1990). The JG 
cells synthesize an inactive precursor, called pre-prorenin, which is then processed 
into prorenin by the cleavage of a single amino acid from the C-terminus. Prorenin is 
also biologically inactive and further glycosylation and proteolytic cleavage leads to 
formation of renin (Dzau et al., 1988). Circulating renin is mostly derived from the 
JG cells but renin production has also been detected in several organs (Griendling, 
1993).  
 
Several mechanisms are involved in renin secretion from the JGA. Renin secretion is 
stimulated in response to decreased pressure or stretch; conversely increased pressure 
inhibits renin secretion (Wagner & Kurtz, 1998). Renin release is also regulated by 
the tubular fluid composition at the macula densa (MD) (Castrop et al., 2010). The 
macula densa is an area of closely packed specialized cells lining the wall of the 
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distal tubule at the point of return of the nephron to the afferent arteriole of its parent 
glomerulus. It has been shown that renin secretion is inhibited following renal 
arterial infusion of NaCl. Since MD cells do not have direct contact with the JGA, 
secondary messenger signalling is require to transmit the signal from the MD to the 
JGA. It has been shown that adenosine release from MD cells acts as a chemical 
signal to inhibit renin release from the JGA (Komlosi et al., 2004,). Furthermore 
renin release is also controlled by the sympathetic nervous system, several endocrine 
and paracrine hormones and extracellular Ca++ concentration (Castrop et al., 2010, 
Hackenthal et al., 1990).  
 
There is ample evidence for the existence of tissue RAS in addition to circulating 
RAS. All the components of the RAS are available in several organ systems such as 
the brain, heart, adrenal gland and kidney (Bader et al., 2001; Morimoto & Sigmund, 
2002). These local RAS also play a vital role in blood pressure regulation. It has been 
reported that antihypertensive effects of ACE inhibition are better correlated with 
tissue ACE inhibition rather than plasma ACE. Furthermore RAS inhibitors have 
also proved effective in treating hypertensive patients with normal or low levels of 
circulating RAS (Dzau et al., 2001). Intrarenal RAS has a regulatory role on blood 
pressure through the modulation of renal function (Navar et al., 1997) whereas brain 
RAS modulates blood pressure by facilitating neurotransmission and releasing 
vasopressin (Costa & Majewski, 1988; Steckelings et al., 1992).  
 
A series of transgenic studies have been used to address the importance of the tissue 
or paracrine RAS. Double transgenic mice expressing kidney androgen-regulated 
hAGT and a systemically expressed hREN were reported to have increased blood 
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pressure with normal circulating ANG ΙΙ levels following testosterone treatment 
(Ding et al., 1997). The increase in blood pressure was paralleled by a high 
concentration of urinary hAGT. Similarly when mice expressing hAGT under a 
brain-specific promoter were crossed with mice expressing hREN systemically, a 
15mm Hg increase in blood pressure was reported (Morimoto et al., 2001). These 
observations clearly indicate the contribution of local RAS in blood pressure 
regulation. 
 
The renin locus is an area of research interest. In humans, rats and some mouse 
strains, there is only one renin gene. Other mouse strains, however, have two renin 
genes at this locus, designated Ren1d and Ren2 (Mullins et al., 1982). This is 
thought to have arisen from a gene duplication event approximately 3 million years 
ago in the mouse lineage (Dickinson et al., 1984). Studies in two renin gene mice 
exemplify the role of renin in blood pressure control. Mice with two renin genes have 
much higher plasma renin concentrations compared to one renin gene carrying mice. 
Blood pressure is also greater in mice with two renin genes (Wang et al., 2002).  
 
1.2.3 Angiotensin converting enzyme 
 
Angiotensin converting enzyme (ACE) is a dipeptidyl carboxipeptidase, which 
cleaves a dipeptide from the carboxyl terminal of ANG Ι to form the octapeptide 
ANG ΙΙ (Edros, 1975; Peach, 1977). ACE is predominantly synthesized in the 
pulmonary vasculature. ACE is also enzymatically active for a range of other small 
peptides such as inactivation of bradykinin.  Thus, biologically, the actions of ACE 
potentiate vasoconstriction by producing ANG ΙΙ and inactivating the vasodilator 
bradykinin. ACE has also been detected in the glomerular endothelial cells and 
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proximal tubule of the kidney (Paul et al., 2006). A homolog of ACE, termed ACE2, 
has been detected in the heart, kidney and testis (Donoghue et al., 2000). ACE2 also 
cleaves ANG Ι but it removes only a single peptide from the COOH-terminal to 
generate ANG-(1-9) whose function is unknown (Vickers et al., 2002). Subsequently 
ANG-(1-9) undergoes further cleavage by ACE to yield ANG-(1-7) which exerts a 
vasodilatory effect (Ferrario et al., 1997; Ren et al., 2002) upon binding with Mas 
receptors (Lemos et al., 2005). Moreover ACE2 also yields ANG-(1-7) by direct 
degradation of ANG ΙΙ (Rice et al., 2004). Angiotensin II can also be generated from 
angiotensin I by a serine protease chymase (Paul et al., 2006). In addition, non-renin 
enzymes, including tonin and cathepsin are able to generate angiotensin II directly 
from angiotensinogen (Urata et al., 1994; Urata et al., 1996).  
 
1.2.4 Angiotensin ΙΙ 
 
Angiotensin ΙΙ (ANG ΙΙ) is the primary active component of the RAS. ANG ΙΙ has a 
very short biological half-life and its biological actions are mediated upon binding 
with its receptors. Although ANG ΙΙ is the main effector of the RAS, some 
biologically active components may also be formed by further cleavage of ANG ΙΙ 
by amonipeptidase (Ahmad & Ward, 1990) or by endopeptidase (Welches et al., 
1991; Yamamoto et al., 1992).  Fragmented peptides such as ANG ΙΙΙ (2-8) and 
ANG ΙV (3-7) produced by aminopeptidase-mediated cleavage have the same action 
as ANG ΙΙ although they are less potent (Goodfriend and Peach, 1975). ANG ΙΙΙ is 
considered as the main effector of the RAS in the brain (Harding & Felix, 1987). On 
the other hand endopeptidase-mediated cleavage of ANG ΙΙ produces ANG (1-7) 
 29 
which is a vasodilator and causes natriuresis and diuresis (Handa et al., 1996; Vallon 
et al., 1998). 
 
1.2.5 ANG II receptors 
 
At the cellular level, action of ANG II is mediated mainly by two G-protein coupled 
receptors AT1 and AT2. The effects of ANG II to maintain blood pressure are mainly 
mediated by AT1 receptors (Timmermans et al., 1993). In rodent two subtypes of AT1 
receptors termed AT1A and AT1B have been identified and they share substantial 
sequence homology. However AT1A receptors are predominant and considered the 
closest homologue to the single human AT1 receptor (Burson et al., 1994). AT1 
receptor activation stimulates phospholipase C, which in turn produces two 
secondary messengers, inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 
stimulates the release of Ca++ from intracellular storage and DAG induces protein 
kinase C (PKC) activity, both of which cause vasoconstriction (Capponi, 1996; 
Griendling et al., 1996). In several tissues AT1 receptor binding mediates inhibition 
of adenylate cyclase. This attenuates the production of the pro-vasodilation 
secondary messenger cAMP, thereby potentiating the direct vasoconstriction effects 
of ANG ΙΙ  (Apfeldorf & Rasmussen, 1988; Pobiner et al., 1985). The AT1 receptor 
also activates phospholipase A2 and D which leads to the production of 
prostaglandins which partially attenuates the vasoconstrictor effect of ANG ΙΙ 
(Capponi, 1996; Griendling et al., 1996). Moreover, AT1 receptor binding stimulates 
the influx of Ca++ into the cell by the opening of Ca++ channels. These mechanisms 
have been linked to aldosterone production and release (Apfeldorf & Rasmussen, 
1988).  
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AT1 receptors are expressed in a variety of organ systems such as the brain, adrenal 
gland, heart, vasculature and kidney. Actions in each of these systems serve to 
maintain blood pressure and fluid and electrolyte balance. In the vascular system, 
ANG II stimulation of the AT1 receptor causes potent vasoconstriction resulting to an 
increase in blood pressure (Ito et al., 1995). In the adrenal cortex, AT1 receptor 
activation mediates the secretion of aldosterone, which in turn causes the tubules of 
the kidneys to retain sodium and water (Masilamani et al., 1999). In the brain, 
pressor responses are observed upon intraventricular injection of ANG II, an effect 
mediated by AT1 receptors (Davisson et al., 2000). In the kidney, AT1 receptor 
activation by ANG ΙΙ causes renal vasoconstriction and influences sodium and water 
reabsorption in several sections of the nephron. Moreover, AT1 activation inhibits 
renin secretion by the JGA and thus exerts a negative feedback on the RAS: the so 
called “short-loop” feedback mechanism (Ichikawa & Brenner, 1980). 
 
The AT2 receptor is found in several organs such as the heart (Tsutsumi et al., 1998; 
Wharton et al., 1998), glomeruli, renal tubules and renal blood vessels (Ozono et al., 
1997) and the adrenal medulla (Allen et al., 1999; Breault et al., 1996). The 
functional role of the AT2 receptor is not fully characterized but several studies have 
described contributions to apoptosis, antiproliferation, differentiation and 
vasodilation (Csikos et al., 1998; Horiuchi, 1996).  In the kidney, AT2 receptors are 
involved in the production of cGMP, NO and prostaglandin and might, therefore, 
have a role in blood pressure regulation antagonistic to that of the AT1 receptor- 
mediated pathways (Siragy & Carey 1996; Siragy & Carey 1997). The 
countervailing influence of AT2 receptors is also apparent in terms of hypertensive 
organ damage. In the kidney, for example, high levels of angiotensin II cause 
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glomerular and tubulointerstitial injury which are mediated by AT1 receptors. In 
contrast, over expression of the AT2 receptor exerts a counter-regulatory mechanism 
to the adverse effects induced by AT1 receptor in kidney disease. (Tejera et al., 2004; 
Vazquez et al., 2005) 
 
1.3 Renal sodium handling 
 
1.3.1 Role of renal haemodynamics 
 
Renal blood flow (RBF) and glomerular filtration rate (GFR) are the two major 
determinants of renal haemodynamics. RBF is the volume of blood delivered to the 
kidneys per unit time. RPF is the rate at which plasma flows through the kidney. By 
estimating the rate of plasma flow through the kidneys, one can obtain an estimate of 
the rate of total blood flow through the kidneys. The normal rate of plasma flow 
through both kidneys of a 70 kg human is about 650 ml/min, and the normal rate of 
blood flow is about 1200 ml/min. Plasma makes up about 55% of the total blood 
volume and the plasma flow rate is about 55% of the total blood flow rate. Renal 
blood flow is not greatly influenced by systemic blood pressure due to 
autoregulation, (see section 1.3.1.2, below) and thus GFR, the volume of fluid that 
filters out of the plasma through the glomerular capillary walls into Bowman's 
capsules is influenced chiefly by factors that determine the balance of Starling’s 
pressures across the capillary wall. These pressures are i) hydrostatic pressure, the 
net effect of which is to favour filtration; and ii) capillary oncotic pressure whereby 
the retention of proteins in the plasma opposes filtration.  
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1.3.1.1 Regulation of GFR 
 
GFR is regulated by the sympathetic nervous system, hormones and autocoids. These 
factors control GFR by intrarenal changes in RBF: the relative constriction of the 
pre- (afferent) and post-(efferent) glomerular arterioles will determine glomerular 
hydrostatic pressure  and thus the force favouring filtration. In addition, vasoactive 
agents can change the glomerular surface area available for filtration by inducing 
contraction or relaxation of the glomerular mesangial cells (Mitchell et al., 1992). 
Increased afferent arteriolar constriction reduces renal blood flow and hydrostatic 
pressure in the glomerular capillaries (PGC), causing a reduction in GFR.  Efferent 
arteriolar constriction generally increases glomerular hydrostatic pressure thus 
increases GFR. However a reduction in renal blood flow causes an increase in 
glomerular colloid osmotic pressure. As a consequence, during severe efferent 
arteriole constriction, the colloid osmotic pressure exceeds glomerular hydrostatic 
pressure and the net force for filtration actually drops which causes GFR to reduce. A 
reduction in glomerular capillary filtration coefficient reduces GFR.  
 
1.3.1.2 Autoregulation of GFR and RBF 
 
Increased arterial pressure tends to increase glomerular hydrostatic pressure, which 
increases GFR. However the intrinsic feedback mechanism of the kidney maintains 
RBF and GFR relatively constant. This feedback mechanism is termed 
autoregulation. Two mechanisms interact to provide highly efficient renal 
autoregulation: the tubuloglomerular feedback mechanism and the myogenic 
mechanism. 
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1.3.1.2.1 Tubuloglomerular feedback 
 
In the tubuloglomerular feedback (TGF) mechanism, macula densa (MD) cells in the 
initial portion of the distal tubule sense the NaCl concentration of the tubular fluid 
and influence filtration at the glomerulus of origin. Any alterations that cause 
increased sodium reabsorption before the MD result in a decrease in the 
concentration of NaCl at the MD cells. This induces a signal from the MD cells that 
has two effects. It increases glomerular hydrostatic pressure by decreasing afferent 
arteriole resistance (Braam et al., 1993; Navar et al., 1996). This also causes 
vasoconstriction of the efferent arteriole by increasing renin secretion and 
consequently the formation of ANG ΙΙ (Mitchell, 1992; Mitchell & Mullins, 1995). 
As a result of the synergistic effects of theses two events, GFR returns toward 
normal, which ultimately returns distal sodium delivery towards normal, so that 
sodium and water excretion can be maintained. An opposite series of action occurs 
when proximal tubular reabsorption is reduced. By this mechanism TGF allows 
precise control of the renal excretion of sodium and water. A general structure of the 
glomerulus along with the afferent and efferent arteriole, the macula densa cells and 






1.3.1.2.2 Myogenic autoregulation 
 
Another mechanism of RBF and GFR regulation is the ability of individual blood 
vessels to respond to changes in wall tension, occurring in response to alterations in 
arterial pressure. This activates a vascular sensor element that regulates vascular 
smooth muscle tone. Existence of an autoregulatory activity when the TGF response 
is blocked supports a contributory role of the myogenic mechanism in the 
autoregulatory responses of the renal vasculature (Takenaka et al., 1994). 
Figure. 1.2 Structure of the glomerulus, indicating the juxtaposition of the granular juxtaglomerular  
cells of the afferent arteriole and the epithelial cells of the macula densa in the same nephron. Taken 
from Mullins et al., 2006 
 
 35 
1.3.2 Renal sodium transporters 
 
Renal sodium handling is vitally important for body fluid maintenance and the long-
term regulation of blood pressure. Along with renal haemodynamics, renal sodium 
handling largely depends on the regulation of renal tubular transporters. Sodium is 
freely filtered at the glomerulus and subsequently 99% of the filtered sodium is 
reabsorbed by the combined action of ion channels, ion exchangers and ion 
transporters along the nephron. A brief overview of sodium transport in the 
individual nephron segments is given below.  
 
1.3.2.1 Proximal tubule  
 
The proximal tubule is the first part of the nephron leading from the Bowman’s 
capsule to the loop of Henle and lies in the cortex of kidney (Fig. 1.2A). About 65% 
of filtered sodium is reabsorbed by the proximal tubule. The apical membrane of the 
proximal tubule is enriched with at least 20 different sodium co-transporters coupled 
with organic substrates such as amino acids and carbohydrates. Nevertheless, these 
transporters collectively mediate only 10% of the proximal tubule sodium 
reabsorption (Greger, 2000). The rest of sodium transport in the proximal tubule 
mainly occurs by a counter-transport mechanism, the sodium-hydrogen exchanger 
(NHE3) (Wakabayashi et al., 1997). This exchanger reabsorbs sodium whilst 





























Figure. 1.2 Renal sodium transport mechanisms. A: percentage sodium reabsorption over the length of the 
nephron. Principal mechanisms of sodium reabsorption are shown in the proximal tubule (B), the thick 
ascending loop of Henle (C), the distal convoluted tubule (D), and the collecting duct (E). Taken from 
Mullins et al., 2006. 
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in the proximal tubule, as for all other nephron segments, is created by the 
basolateral (Na+-K+)-ATPase (Skou, 1992). This pump extrudes 3 Na+ and takes up 2 
K+ for each ATP hydrolyzed. This sodium potassium ATPase pump creates a 
concentration gradient, which causes sodium to move into the cell.  
 
1.3.2.2 Loop of Henle 
 
The loop of Henle consists of three distinct sections: the thin descending limb, the 
thin ascending limb and the thick ascending limb. About 25-30% of filtered NaCl 
and 20% of filtered water is reabsorbed at this nephron segment. Water reabsorption 
mainly occurs through the highly permeable thin descending limb. In contrast, both 
the thin and thick ascending limbs are virtually impermeable to water. Sodium is 
mainly reabsorbed through the thick ascending limb, coupled directly or indirectly to 
the activity of Na-K-2Cl cotransporter (Fig. 1.2C) (Greger, 1985). As in the proximal 
tubule, the basolateral sodium-potassium ATPase pump maintains a low intracellular 
sodium concentration and provides a favourable gradient for the movement of 
sodium from the lumen into the cell. Efficient operating of NKCC2 requires K+ to 
recycle across the apical membrane through a K+ channel (ROMK) and chloride to 
exit basolaterally through a chloride channel (CLCNKB) (Hebert, 2005). The 
potassium recycling creates a lumen-positive electrical potential gradient, which 
drives the reabsorption of cations through the paracellular pathway (Hebert, 2005). 
The TAL also has a sodium-hydrogen counter-transport mechanism like the proximal 
tubule, which also mediates sodium reabsorption and hydrogen secretion. 
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1.3.2.3 Distal convoluted tubules 
 
About 5% of filtered sodium is reabsorbed in this part of the nephron. The sodium 
reabsorption processes are driven by the basolateral (Na+-K+)-ATPase. This pump 
maintains a low sodium concentration inside the cell which favours Na+ uptake 
across the apical membrane by the Na+Cl− cotransporter (Fig. 1.2D) (Gamba et al., 
1993). Na+ is pumped out by the (Na+-K+)-ATPase and Cl- leaves the cell via the 
basolateral KCl symporter. Sodium reabsorption is also mediated by the sodium-
hydrogen exchange (NHE2), but to a lesser extent. 
 
1.3.2.4 Connecting tubules and collecting duct 
 
The transport of sodium in the connecting tubule and collecting duct is responsible 
for final adjustment. This site reabsorbs only 4% of the total filtered sodium. The 
absorptive process again depends on the basolateral (Na+-K+)-ATPase. Na+ enters the 
cell via Na+ channels, epithelial Na+ channels (ENaC), along its electrochemical 
gradient (Fig. 1.2E) (Garty & Palmer, 1997). The Na+ current through these channels 
causes a strong depolarization of the apical membrane. Due to this depolarization the 
cellular potassium reaches above its equilibrium concentration. Thus K+ leaves the 







1.4 Role of angiotensin ΙΙ  on blood pressure 
regulation 
 
Angiotensin ΙΙ acts on multiple sites in the body such as the kidney, brain, adrenal 
and vascular smooth muscle. Through its combined effect on these sites the RAAS 




It has been shown in several studies that ACE inhibition has a significant role in the 
treatment of heart failure (Swedberg & Kjekshus, 1988), myocardial ischaemia 
(Elfellah & Ogilvie, 1985; van Gilst 1986) and hypertension (Johns et al., 1980; 
Baker et al., 1980). Upon binding with AT1 receptors, ANG II has effects on the 
regulation of heart rate, contractility and cell growth. ANG II-induced positive 
chronotropic effects have been demonstrated in dogs (Kobayashi et al., 1978) and 
rats (Li et al., 1996) and other experimental animals. A marked suppression of the 
chronotropic action is observed following AT1 receptor blockade, however β-
adrenoceptor antagonists do not have any influence on this effect. This confirms that 
the positive chronotropic action of angiotensin II is directly attributable to AT1 
receptor activation and not secondary to release of catecholamines from sympathetic 
nerve terminals within atrial tissues. In the long-term, ANG II exerts cytokine-like 
effects which promote cell growth and migration, extracellular matrix deposition, and 






Angiotensin II acts at several sites in the central nervous system to regulate blood 
pressure. It has been demonstrated that angiotensin II exhibits its regulatory role on 
blood pressure by modulating autonomic nervous system activity (Fink, 1997), the 
hypothalamic-pituitary-adrenal axis (Aguilera & Kiss, 1996) and baroreflex control 
(Averill & Diz, 2000). In addition, AT1 receptor activation induces vasopressin 
secretion (Aguilera & Kiss, 1996) in the brain and ANG II also stimulates thirst and 
sodium appetite (Fitzsimons, 1998). Furthermore ANG II is involved in the 
regulation of neurotransmitters such as noradrenaline and 5- hydroxytryptamine (5-
HT) and inhibits acetylcholine release (Phillips & Sumners, 1998).  
 
Activation of sympathetic nerves reflects both enhanced neurotransmitter release at 
nerve terminals and increased synaptic transmission through sympathetic ganglia 
(Reid, 1992). Since ANG II does not cross the blood brain barrier, circulating ANG 
II can only influence central processes through interaction with receptors in 
circumventricular areas of brain that lack the blood brain barrier (Paton et al., 2008). 
It is postulated that such binding promotes the transmission of nerve signals to other 
brain regions that lie behind the blood-brain barrier, thereby exerting effects such as 
stimulating the release of vasopressin from the posterior pituitary and also drinking 
behavior. (Unger et al., 1988) It is well established that along with the actions of 
peripheral RAS components in certain regions of the central nervous system (CNS), 
an independent RAS also exits in the brain (McKinley et al., 2003). It has been 
shown that a double transgenic mice expressing hAGT under a brain-specific 
promoter and a systemically expressing hREN, were reported to have a 15mm Hg 
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increase in blood pressure (Morimoto et al., 2001). The combined action of both 
circulating and brain RAS is responsible for increased sympathetic nerve activity 
during increased ANG II levels. 
 
1.4.3 The Adrenal Gland 
 
ANG II is a principle regulator of aldosterone biosynthesis in the zona glomerulosa 
of the adrenal cortex. ANG II can act acutely to stimulate aldosterone biosynthesis 
and chronically to increase the capacity of the adrenals to produce aldosterone 
(Müller J. 1995). In acute stimulation, ANG II increases cholesterol availability to the 
inner mitochondrial membrane by the activation of steroidogenic acute regulatory 
(StAR) protein. ANG II stimulates the StAR both in vitro (Cherradi et al., 1997, 
Betancourt-Calle et al., 2001) and invivo (Peters et al., 1998). Following the 
translocation of cholesterol to the inner mitochondrial membrane, ANG II also 
stimulates the expression of enzymes which are involved in subsequent steps of 
aldosterone synthesis such as cholesterol side-chain cleavage (Bird et al., 1996). 
ANG II also catalyzes the conversion of corticosterone to aldosterone by stimulating 
the transcription of CYP11B2 (Muller 1995). Chronic stimulation by ANG II results 
in zona glomerulosa (ZG) hypertrophy and hyperplasia increased CYP11B2 and 
consequently increased the capacity of the adrenals to produce aldosterone (Connell et 
al., 2008). 
 
At the cellular level the stimulatory action of ANG II on aldosterone production is 
exerted mainly through the AT1 receptors of ZG. This causes phospholipase C to 
stimulate intracellular production of 1,4,5 inositol triphosphate and 1,2-
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diacylglycerol which, in turn, activate protein kinase C. AT1 receptor binding also 
activates calcium/calmodulin-dependent kinases (CaMK), and mitogen-activated 
protein kinase (MAPK, Hunyady & Cat, 2006). Activation of these signalling 
cascades, leading to the release of Ca2+ from the endoplasmic reticulum (ER) and 
subsequent cell membrane depolarization with additional flow of extracellular Ca2+ 
into the cytoplasm. These events culminate with elevated aldosterone production by 
stimulating the early and the late regulatory steps in aldosterone production (Lemarié 
et al., 2008). Aldosterone secretion is also regulated by adrenocorticotropic hormone 
(ACTH). ACTH secretion is in turn regulated through ANG II-mediated activation of 
the central nervous system (Unger et al., 1988). 
 
1.4.4 The Kidney  
 
ANG II is one of the most potent sodium retaining hormones in the body. Sodium 
retention results from the interplay between renal haemodynamic control and direct 
actions on renal tubular sodium transport. In addition, extra-renal mechanisms, 
specifically activation of renal sympathetic nerves and stimulation of aldosterone 
secretion, contribute to the effects of ANG II on sodium balance and thus blood 
pressure regulation.  
 
1.4.4.1 Role of ANG II on the regulation of renal haemodynamics 
 
In the kidney ANG II constricts both the afferent and efferent arterioles of the 
glomerulus (Arendshorst et al., 1999; Navar et al., 1996).  ANG II affects both 
arterioles with similar potency, although some studies indicate a preferential 
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constriction of the efferent arterioles (Carmines & Navar, 1989). The relatively 
greater constriction of the efferent arteriole in response to ANG II serves to maintain 
a proportionally higher glomerular hydrostatic pressure than would be the case if 
both arterioles responded to the same degree. Thus there is a smaller reduction of 
GFR compared to larger decreases in renal blood flow and the filtration fraction rises 
(Carmines et al., 1987). The reduction in GFR is also caused by a reduction in 
glomerular filtration coefficient by ANG II. Glomerular filtration coefficient is 
influenced by the changes in contractility of mesangial cells caused by ANG II 
receptor binding (Paul et al., 2006; Sharma et al., 1998). Along with its direct 
effects, ANG II also stimulates the release of several vasoactive components such as 
nitric oxide, arachidonic acid metabolites and endothelin. The vasoconstrictory 
action of ANG II is associated with increases in cytosolic calcium and enhanced 
phospholipase A2 activity. These in turn stimulate the action of endothelial NO 
synthase and cyclooxygenase. As a result, the constrictor actions of ANG II are, to a 
degree, offset by the vasodilatory action of these vasodilators (Zou et al., 1998). NO 
buffers the action of ANG II with a greater potency on afferent arterioles again 
preserving hydrostatic pressure and GFR (Ito et al., 1993). Another modulator of 
ANG II-mediated vasoconstriction is endothelin 1 (ET1). ET1 gene over expression 
and synthesis in vascular smooth muscle cells is augmented by ANG II (Dohi et al., 
1992; Rossi et al., 1999).  
 
In addition to direct constriction of the glomerular arterioles and mesangium, ANG II 
also modulates the sensitivity of the TGF mechanism. (Navar et al., 1996; Paul et al., 
2006) Studies in AT1R null mice indicate that ANG II does not mediate TGF 
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(Schnermann et al., 1997). Nevertheless, several studies have provided evidence that 
the level of activity of ANG II modifies the sensitivity of the vascular and mesangial 
elements to macula densa feedback (Mitchell et al., 1992; Schnermann et al., 1997; 
Traynor et al., 1999). An enhanced TGF response is found during exogenous ANG II 
infusion. (Mitchell & Navar, 1988). Conversely, ANG II antagonist or ACE 
inhibitors and salt loading attenuates TGF (Bramm et al., 1995; Ploth, 1983; 
Schnermann, 1998b). It has also been demonstrated that TGF responses are markedly 
attenuated in both AT1 receptor knockout and ACE-deficient mice (Scharmann et al., 
1997; Traynor et al., 1999). The enhanced sensitivity of TGF by ANG II is mediated 
by the stimulation of macula densa sodium chloride transport. The synergistic actions 
of increased ANG II to increase tubular reabsorption rate and enhanced TGF 
sensitivity cause a sustained reduction in distal nephron volume delivery, which 
maintain sodium balance more effectively to regulate blood pressure (Kobori et al., 
2007). 
 
1.4.4.2 Role of ANG II on tubular sodium transport 
 
1.4.4.2.1 Role of ANG II on proximal tubule sodium transport 
 
Considerable evidence suggests that ANG II increases proximal tubular sodium 
reabsorption. However it is difficult to separate out the direct effect of ANG II on 
tubular transport from its effect on renal haemodynamics. A rat proximal tubule 
microperfusion study found that ANG II stimulated proximal tubular sodium 
reabsorption when added to peritubular capillaries at physiological concentrations 
(Harris et al., 1977): this effect related to activation of the (Na+-K+)-ATPase (Garvin 
et al., 1991). Additionally, physiological concentrations of ANG II enhance NHE3 
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mediated sodium transport in the proximal tubule due to increased expression of 
protein (Dixit et al., 2004). Stimulatory effects of ANG II on sodium transport have 
also been found in primary cell cultures (Thekkumkara et al., 1998) and in kidney 
cortex slices from the rat kidney (Munday et al., 1971). In combination, ANG II, 
acting from either the blood or luminal side will stimulate the net reabsorption of 
sodium by the proximal tubule.  
 
1.4.4.2.2 Role of ANG II on Thick Ascending Limb (TAL) sodium 
transport 
 
In thick ascending limb (TAL) the apical sodium transport is mediated by two 
transporter proteins, Na+-K+-2Cl- cotransporter (NKCC2) and Na+/H+ exchanger 
(NHE3). A marked increase in both NHE3 and NKCC2 activity has been observed in 
response to ANG II treatment in vivo (Kwon et al., 2003). However a biphasic 
response of NKCC2 co-transport activity to ANG II has also been reported. Low 
concentrations (10-16 to 10-12 M) of ANG II inhibit the activity and higher 
concentrations (10-11 to 10-6 M) stimulate the activity in mTAL cells (Amlal et al., 
1998). A significant increase in NKCC2 co-transporter has also been reported in rats 
with congestive heart failure, which have high plasma renin levels and presumably 
high plasma ANG II levels. Furthermore treatment of rats with congestive heart 
failure with the AT1-receptor blockade normalized the abundance of NKCC2 
(Staahltoft et al., 2002). Several lines of evidence also showed that aldosterone does 
not have any regulatory effect on the abundance of TAL sodium transporters 
(Masilamani et al., 1999, Neilsen et al., 2002). Thus ANG II regulation of NHE3 and 
NKCC2 abundance is directly mediated by ANG II. 
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1.4.4.2.3 Role of ANG II on distal convoluted tubule sodium transport 
 
The sodium chloride cotransporter (NCC) is expressed in the apical membrane of the 
distal convoluted tubule. In Xenopus oocytes, ANG II increases NCC activation by 
abrogating WNK4-mediated inhibition of NCC (Kahle et al., 2003; Yang et al., 
2005). This effect was prevented by AT1 receptor blockade (San-Cristobal et al., 
2009). This WNK-4 mediated regulation of NCC is also observed in mouse models 
(Lalioti et al., 2006; Yang et al., 2007). A further study suggested that ANG II 
induces phosphorylation of NCC at key regulatory sites through the SPAK/OSR1 
kinases (San-Cristobal et al., 2009; Talati et al., 2010). In rat, an acute trafficking of 
NCC from the sub-apical membrane to apical plasma membrane was observed 
following ANG II infusion (Sandberg et al., 2007). Conversely the ACE inhibitor 
captopril reverses the trafficking. This indicates that ANG II also plays a vital role in 
NCC trafficking (Sandberg et al., 2007). 
 
Dietary sodium restriction increases plasma aldosterone levels, which in turn 
increases the NCC abundance in distal convoluted tubules. A similar scenario is also 
observed when animals were either infused with aldosterone or oral administration of 
synthetic mineralocorticoid (Kim et al., 1998). Together, these data indicate that 
NCC is directly regulated by aldosterone. Dietary sodium restriction in mice 
increases renal NCC expression and its phosphorylation at Thr53, Thr58 and Ser71. 
However this response is attenuated in the SGK1 knockout mouse. This indicates the 
contributory role of SGK1 on the regulation of NCC expression and phosphorylation 
by dietary sodium restriction (Vallon et al., 2009). 
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1.4.4.2.4 Role of ANG II in connecting tubule and collecting duct sodium 
transport 
 
The amiloride sensitive sodium channel, ENaC, is localized in the connecting tubule 
and the collecting duct and plays a vital role in the regulation of renal sodium 
excretion and blood pressure regulation (Lifton et al., 2001). ENaC is a hetero-
oligomer consisting of three subunits, namely α,β and γ (Canessa et al., 1994). 
Among these subunits, the α subunit is considered as the rate limiting subunit for 
assembly of the mature ENaC complexes (Beutler et al., 2003; May et al., 1997). 
Aldosterone is one of the most important regulators of ENaC; it strongly up regulates 
the abundance of αENaC, both at the protein and mRNA levels (Stokes & Sigmund, 
1998). Elevated abundance of αENaC was observed when rats were placed on either 
dietary sodium restriction or infused with aldosterone (Masilamani et al., 1999). The 
abundance of β and γ subunits was unchanged indicating the selective induction of 
αENaC by aldosterone. Immunofluorescence study showed a redistribution of ENaC 
to the apical region of the collecting duct principal cells in these animals 
(Butterworth, 2010). Western blot analysis also revealed that aldosterone induced a 
shift in molecular weight of αENaC from 85 kDa to 70 kDa which might be 
responsible for the activity of the channel by increasing the open probability 
(Masilamani et al., 1999). 
 
Several studies have shown that the serum glucocorticoid- inducible serine/threonine 
kinase (SGK1) has a regulatory role in the control of ENaC-mediated sodium 
transport (Chen et al., 1999; Naray-Fejes-Toth et al., 1999). Coexpression of the 
SGK1 significantly enhances the activity of ENaC heterologously expressed in 
Xenopus oocytes (Chen et al., 1999; Naray-Fejes-Toth et al., 1999) and A6 cells 
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(Faletti et al., 2002). SGK1 mediated activation of ENaC is partly controlled by 
phosphorylation of Nedd4. Nedd4 is an ubiquitin protein which interacts with ENaC, 
causing ubiquitination and degradation of the channel complex. Phosphorylation of 
Nedd4 by SGK1 diminishes its binding affinity for the target protein and thus 
disrupts the ubiquitination of ENaC (Debonneville et al., 2001; Eaton et al., 2010; 
Snyder et al., 2002). This causes an increase in ENaC protein abundance in the cell 
membrane (Debonneville et al., 2001). Thus inhibition of ENaC degradation by 
SGK1 is considered to participate in the regulation of renal sodium excretion by 
aldosterone. 
 
Although aldosterone plays a vital role controlling the sodium transport in the distal 
nephron, several studies have also identified a direct contribution of ANG II in these 
segments. (Peti-Peterdi et al., 2002; Wang & Giebisch, 1996). In isolated perfused 
CCD segments dissected from rabbit kidneys, ANG II markedly increased the apical 
entry of sodium. This effect was blocked completely by the specific ENaC channel 
blocker benzamil (Peti-Peterdi et al., 2002). Moreover, it has also been shown that 
AT1 receptor blockade markedly decreased the abundance of αENaC in NaCl 
restricted rats. Conversely αENaC abundance was significantly increased in rat 
kidney cortex by systemic infusion of angiotensin II (Beutler et al., 2003). In 
summary ANG II regulates the sodium absorption by the kidney in part by AT1 
receptor-mediated regulation of the abundance of αENaC. Furthermore, a targeted 
proteomics approach in AT1a receptor knockout mice has revealed that during dietary 
NaCl restriction the abundance of αENaC and NCC were markedly decreased in 
knockout mice compared to wild type mice, although circulating aldosterone levels 
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in knockout mice were significantly higher (Brooks et al., 2002). This indicates that 
ANG II directly plays an important role in the regulation of Na+ transporter and 
channel proteins in the "post-macula densa" region of the renal tubule independent of 
altered circulating aldosterone concentrations. 
 
1.5 Mutations in renal sodium transporters cause 
blood pressure abnormalities/disorders 
 
Mutations in the genes encoding renal sodium transporters, or in genes that influence 
the activity of renal sodium transporters, have been linked to electrolyte and blood 
pressure disorders in humans (Lifton et al., 2001).  Modelling of these defects in 
mice provides a useful tool to study the physiological relationship between renal 
sodium homeostasis and blood pressure control (Schnermann, 2001). Sodium 
transporter defects, for example, can cause a permanent reduction in extracellular 
fluid volume which in turn stimulates renin release and aldosterone synthesis. These 
changes cause an activation of Na+ conservation mechanisms such as adaptation by 
the increased transporter activity in the downstream nephron segment. In most of the 
cases the sodium balance is restored and a steady state is achieved. But when sodium 







1.5.1 Proximal tubule transporters  
 
As discussed earlier NHE3 is the major transporter in the proximal tubule which 
accounts for 50-60% of sodium reabsorption. However NHE3 knockout mice exibit 
only a mild volume depletion and hypotension (Schultheis et al., 1998; Wang et al., 
1999). It has been shown that NHE3 deletion results in the delivery of more sodium 
to the MD, which causes a reduction in blood flow and GFR by resetting the TGF 
(Lorenz et al., 1999). The loss of NHE3 is also compensated by enhanced expression 
of the Na-phosphate cotransporter, and the collecting duct γ-ENaC subunit (Brooks 
et al., 2001). Up-regulation of NHE2 in the early distal tubule has also been 
demonstrated (Bailey et al., 2004) and these changes may well reflect significant 
activation of the RAS. NHE3 null mice actually show an increased, rather than 
diminished, tubular sodium reabsorption (Bailey et al., 2004), which illustrates the 
redundancy of sodium transport within the kidney.  
 
Similarly, deletion of aquaporin 1 (aqp1) which causes impaired proximal tubular 
sodium reabsorption, was found to result in moderate hypotension (Schnermann et 
al., 1998a). Proximal impairment is compensated by activation of TGF. To 
understand the individual role of TGF and distal sodium reabsorption the Aqp1 -/- 
mouse was crossed with the adenosine A1a receptor knockout mouse, which has a 
defective TGF. Surprisingly, the double knockouts maintained the sodium balance 
(Hasimoto et al., 2004). This indicates the importance of distal tubular sodium 
reabsorption in sodium balance and may explain why no severe blood pressure 
defects associated with impaired proximal tubule function have been identified in 
humans. 
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1.5.2 Thick Ascending Limb (TAL) transporters  
 
Genetic defects in any of the TAL transporters such as NKCC2, ROMK, CLCNKB 
cause Bartter’s syndrome. It is characterized by severe polyuria, low plasma 
potassium, alkalosis, hypercalciuria, proteinuria and low blood pressure (Hebert, 
2003). Knockout mice for NKCC2 die within 2 week of birth from severe volume 
depletion, which demonstrates the importance of the transporter in fluid balance 
(Takahashi, 2000). Mouse Kcnj1 knockouts represent Bartter’s syndrome caused by 
a null mutation in the ROMK gene (Lu et al., 2002). Similar to NKCC2 knockout 
mice, the majority of null mutants die within 3 week of age. In spite of reductions in 
GFR the survivors had marked renal sodium loss. This may be due to an inability to 
correct renal sodium handling by TGF. Thus K+ channels are required for efficient 
sensing of luminal sodium by MD cells (Vallon, 1997).  
 
1.5.3 Distal convoluted tubule transporter  
 
Loss-of-function mutations in the gene encoding NCC at the distal convoluted tubule 
cause Gitleman’s disease. This disease is characterized by hypokalemia, metabolic 
alkalosis and mild hypotension. Mice lacking NCC represent the animal model for 
Gitleman’s disease and do not show any salt wasting phenotypes (Schultheis et al., 
1998), since the function of NCC is compensated by an increased abundance of the 
γ-subunit of ENaC (Brooks et al., 2001). Another autosomal dominant disorder 
called Gordon’s syndrome, characterized by hypertension and hyperkalemia, is also 
linked with increased NCC activity since thiazide treatment can correct this disorder 
(Wilson et al., 2001). However there is no significant linkage between Gordon’s 
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syndrome and the NCC gene locus (Gamba, 2005). It has been observed that 
independent mutation in two serine-threonine kinase family WNK4 (Wilson et al., 
2001) and WNK1 (Newhouse et al., 2005) is responsible for this disorder. The 
mutations that cause Gordon’s disease produce a gain-of-function for WNK1 or loss-
of-function of WNK4 (Flatman, 2007). Both WNK1 and WNK4 modulate the NCC 
activity by phosphorylation through SPAK and ORS1 kinases (Richardson et al., 
2008; San-Cristobal et al., 2009).  
 
1.5.4 Connecting tubule and collecting duct transporters 
 
Loss-of-function mutations in any of the three ENaC subunits leads to pseudohy-  
poaldosteronism type I, which results in sodium wasting, hypotension, hyperkalemia 
and high mortality immediately after birth (Chang et al., 1996; Strautnieks et al., 
1996). Several gene inactivation studies for the individual three subunits of ENaC 
identified their role in sodium reabsorption and survival.  Mice with α-ENaC 
knocked out die within 40 hour of birth from failure to clear their lungs (Hummler et 
al., 1996). β-ENaC and γ-ENaC null mutants exhibit early renal dysfunction that 
leads to death from dehydration and hyperkalemia shortly after birth (Barker et al., 
1998; McDonald, 1999). Sodium reabsorption defects in the terminal nephron cause 
severe salt wasting since no other mechanisms are able to compensate for them. This 
results in severe volume depletion and death.   
 
Liddle’s syndrome (Liddle et al., 1983) is a monogenetic form of arterial 
hypertension caused by a gain in function mutation or deletion of ENaC. It is caused 
by specific mutations at the conserved PY motif in either β- or γ-ENaC. Ubiquitin 
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ligases, such as Nedd4-2, interact with the PY motif, leading to ubiquitination and 
degradation. The mutation in the PY motif rescues the ENaC subunits from 
degradation or internalization by Nedd4-2 (Kamynina et al., 2001). This leads to an 
increase in ENaC activity, and increased water and salt reabsorption in the renal 
collecting tubules (Schild et al., 1996).  
 
1.6 The mRen2 model of hypertension 
 
It is well recognized that the renin-angiotensin system is involved in the regulation of 
blood pressure and fluid homeostasis. This enzyme cascade is one of the well 
characterized systems that contribute to the pathogenesis of polygenetic essential 
hypertension. Several experimental animal models have been developed to explain 
the hypertensionogenic mechanism mediated by the renin-angiotensin system. 
Among them the two-kidney-one-clip (2K1C) Goldblatt (Goldblatt et al., 1934) and 
chronic ANG II infused hypertensive rats the most frequently used ANG II-
dependent models of hypertension. Gene targeting approach has also been used 
extensively to define the precise roles of RAS components in the genesis of 
hypertension (Mullins et al., 2006). It provides the opportunity to study the effect of 
precise molecular genetic intervention to study the complex system of blood pressure 
regulation in whole animal. Several animal models have been developed in the last 
20 years to study the contributory role in the development of hypertension. In the 
current study an inducible hypertensive transgenic rat with the mouse Ren2 gene 
(Kantachuvesiri et al., 2001) has been used.  
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1.6.1 Renin locus 
 
In human and rat only one renin gene is present but mice have two genotypes at the 
renin locus. Some inbred mouse strains such as C57BL/6 and BALB/c contain one 
renin gene (Ren-1c) and are analogous to human and rat. Other strains such as SV129 
and DBA are unique in having two renin genes termed Ren-1d and Ren-2 (Field & 
Gross, 1985). The Ren-1d and Ren-2 genes are closely related and this is thought to 
arise from a gene duplication event that occurred about three million years ago 
(Dickinson et al., 1984). The Ren-1d genes express renin predominantly in the 
juxtaglomerular apparatus of the kidney, whereas the main site for the Ren-2 gene 
expression is submaxillary gland and also in the kidney at very low levels (Sigmund 
& Gross, 1991). All three mouse renin genes share the same overall genomic 
organization and translate into highly homologous proteins. However the product of 
Ren-2 lacks putative consensus sites for asparagine-linked glycosylation. The 
characteristic glycosylation of the Ren-1d  protein may be related to renin secretory 
granule formation in JG cells and maturation of pro-renin. (Clark et al., 1997; 
Mullins et al., 2000). 
 
Targeted disruption of the Ren-1c gene in single renin gene strains has been reported 
to result in a reduction in blood pressure (Takahashi et al., 2005). These mice also 
show undetectable plasma renin, ANG I and ANG II, reduced urinary aldosterone 
and renal morphological changes. Several gene targeting studies have been 
performed to identify individual contributions of the Ren-1d and Ren-2 genes to the 
maintenance of BP in two renin gene carrying mice (Bertaux et al., 1997; Clark et 
al., 1997; Sharp et al., 1996; Pentz et al., 2001). It has been demonstrated that 
targeted disruption of the Ren-1d gene in two renin gene carrying mice causes a 
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reduction in blood pressure in female mice along with a lower plasma renin 
concentration but not in male animals (Clark et al., 1997). This indicates that the 
production of renin from Ren-2 is adequate to compensate the loss of Ren-1d in male 
mice which express larger amounts of Ren2 in the submandibular gland but could not 
fully compensate in female mice. In contrast, another Ren-1d gene disruption study 
showed a significant reduction in plasma active renin concentration accompanied 
with reduced blood pressure in both sexes (Pentz et al., 2001). Another Ren1d 
deletion strain was reported to have no change in blood pressure, suggesting that the 
product of the Ren-2 gene is physiologically active and can compensate for the loss 
of Ren-1d  (Bertaux et al., 1997). Conversely no change in BP was observed in adult 
mice homozygous for the mutated Ren-2 gene in mice carrying two renin gene 
(Sharp et al., 1996). It has been shown that the presence of two renin genes on a 
C57BL/6J genetic background resulted in a higher baseline BP compared to the wild 
type C57 mice carrying a single renin gene (Wang et al., 2002). Mice with two renin 
genes exhibited 100-fold higher PRA and PRC values, indicating the contribution of 
over activity of the renin-angiotensin-aldosterone cascade. Furthermore, AT1 
receptors blockade showed a marked attenuation in BP in two- but not in one-renin 
gene mice. These observations suggest that the Ren-2 gene is physiologically active 
in two-renin gene mice and participates in the increase in BP under basal conditions.  
 
1.6.2 TGR(mRen2) transgenic rat 
To further assess the role of an additional renin gene, the Ren2 gene was introduced 
in mice carrying a single renin gene. The mouse model transgenic for Ren-2 gene did 
not cause hypertension due to species-specific interaction of the renin-angiotensin 
system. Conversely an increased blood pressure was observed when the renin 
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derived from the submaxillary gland of mouse (product of Ren2 gene) was injected 
into rats (Onoyama et al., 1978). As mouse renin is capable of cleaving rat 
angiotensinogen to produce angiotensin I and increases blood pressure if injected 
into rats, a transgenic rat was created by introducing the mouse Ren2 gene into the 
rat genome (Mullins et al., 1990). This transgenic rat model has given the 
opportunity to study hypertension in which the genetic basis of the disease is known. 
This was the first transgenic rat in hypertension research. 
 
These transgenic rats, TGR(mRen2)27, developed fulminant hypertension by 8 
weeks of age (Mullins et al,. 1990). The homozygotes had higher blood pressure than 
heterozygotes, indicating that the hypertensive phenotype depends on the dose of 
transgene. Blood pressure levels also differ between male and female rats, both in 
heterozygous and homozygous strains (Lee et al., 1996). Furthermore both ACE 
inhibition and AT1 receptor blockade effectively lowered the blood pressure, 
indicating that the hypertension is ANG ΙΙ-dependent (Bader et al., 1992, Mullins et 
al., 1990). The hypertensive phenotype of this model is characterized by suppressed 
circulating renin, ANG I and ANG II. The mRen-2 expression is found in the adrenal 
gland, followed by the thymus, brain, gastrointestinal, urinary tracts, kidney and lung 
(Engler et al., 1998, Mullins et al., 1990). This indicates the role of local RAS as the 
cause of hypertensive phenotype in these rats. But the low mRen-2 expression in the 
kidney suggests the major involvement of extrarenal RAS in this model such as 
adrenal RAS (Sander et al., 1992). However, the aldosterone inhibitor spironolactone 
did not decrease blood pressure, which suggests that other factors must be 
responsible for hypertension in this model (Sander et al., 1992). 
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1.6.3 Inducible Cyp1a1-mRen2 transgenic rat model 
 
The experimental animal models that have been used to study angiotensin ΙΙ- 
dependent hypertension require surgical or pharmacological manipulation or depend 
on the constitutive expression of heterologous transgene to induce angiotensin ΙΙ-
dependent hypertension. To overcome these problems and to get a tightly temporally 
regulated gene expression to induce hypertension, an inducible transgenic rat was 
generated by inserting a mouse renin gene under the control of cytochrome P450 
















 Figure 1.3: Schematic presentation of the transgene induction in Cyp1a1-mRen2 
transgenic rat by I3C. 
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upstream of mRen-2 and introduced into Fischer F344 single cell embryos by 
microinjection. The normotensive transgenic line was considered as transgene 
insertion in neutral genomic site. Further analysis by southern blot and in situ 
hybridization identified the insertion of the transgene in the Y chromosome. The 
inducible promoter Cyp1a1 catalyses the oxidation of a variety of xenobiotic 
compounds such as indole-3-carbinol (I3C) (Campbell et al., 1996; Forrester et al., 
1992; Smith et al., 1995). This promoter is not constitutively expressed; rather is 
highly inducible upon exposure to various aryl hydrocarbons. Initially aryl 
hydrocarbon compounds bind with the aryl hydrocarbon receptor (AhR) which is a 
basic helix-loop-helix transcription factor (Jellinck et al., 1993). Upon binding, the 
AhR crosses the nuclear membrane and binds with specific DNA elements in the 
Cyp1a1 promoter (Loub et al., 1975; Pelkonen et al., 1982). This causes an initiation 
of expression of the Cyp1a1 promoter (as shown in Fig. 1.3). So rats carrying the 
Cyp1a1-mRen2 transgene do not express the mouse Ren2 gene constitutively, but it 
is selectively induced in the liver by dietary administration of I3C. 
 
1.6.3.1 Hypertensive phenotype of Cyp1a1-mRen2 transgenic rat 
 
Continuous dietary administration of I3C in transgenic male rats leads to sustained 
hypertension, whereas the transgene negative rats remained normotensive after I3C 
administration (Kantachuvesiri et al., 2001). Importantly, the severity of 
hypertension in the transgenic rats is dose-dependent (Kantachuvesiri et al., 2001): 
low-dose (0.15% w/w) dietary supplementation of I3C leads to slowly developing 
hypertension, whereas at a higher dose (0.3% w/w) hypertension can enter a 
malignant phase, which in rats is indicated by weight loss, piloerection, hunched 
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posture and polyuria (Mitchell et al., 2006). The hypertension in this model is 
reversible, with the termination of I3C administration resulting in the normalization 
of blood pressure (Kantachuvesiri et al., 2001). Thus this model opens the 
opportunity to study the molecular and cellular events occurring during the 
development and reversion of hypertension.  
 
The expression of mRen2 was mainly detected in the liver and small intestine but it 
was not found in other tissues such as spleen, heart, kidney, lung, adrenal gland, 
aorta, or skin (Kantachuvesiri et al., 2001). After induction for 7 days, all the 
components of the circulating RAS were increased in transgenic rats. The plasma 
prorenin concentration was increased greater than 200-fold, whereas plasma renin 
concentration was increased two-fold. Both ANG II and aldosterone levels in plasma 
were increased in Cyp1a1-mRen2 transgenic rats following induction. This increased 
plasma RAAS level is mainly transgene-derived. Levels of PRA and ANG II 
remained unchanged when the AT1 receptor was blocked during induction, 
suggesting that plasma renin and ANG II level is not under the control of JG 
apparatus-regulated renin secretion (Mitchell & Mullins, 2005). Rather it indicates 
that levels of renin and ANG II depend on transgene induction and are not under the 
control of homeostatic regulation. In the kidney although renin mRNA was markedly 
suppressed in transgenic rats; nevertheless a high level of intra renal ANG II is found 
after induction (Mitchell et al., 2006). However AT1 receptor blockade prevents the 
I3C induced augmentation of ANG II suggesting that elevated intrarenal ANG II 
levels in transgenic rats are mediated by AT1 receptor mediated uptake of circulating 
ANG II or receptor mediated stimulation of the intrarenal RAS (Mitchell et al., 
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2006). Attenuation of the hypertensive phenotype by AT1 receptor blockade indicates 
that AT1 receptor activation by elevated plasma and intrarenal ANG II levels 
primarily mediates the development and maintenance of malignant hypertension in 
Cyp1a1-mRen2 transgenic rats (Mitchell & Mullins, 2005; Mitchell et al., 2006; 
Vanourková et al., 2006). A higher plasma and urinary aldosterone was reported in 
this transgenic rat following induction. However inhibition of MR failed to alleviate 
hypertension, suggesting that MR activation by elevated circulating aldosterone 
levels does not contribute markedly to the increased arterial pressure following 
induction of this transgenic rat. Nevertheless, alleviation of proteinuria upon MR 
blockage indicates the contributory role of aldosterone in renal damage (Ortiz et al., 
2007a).  
 
1.6.3.2 End organ damage 
 
In various hypertensive conditions ANG II mediates the pathogenesis of renal tissue 
injury by inducing inflammatory mediators and immune cells (Bledsoe et al., 2006; 
Cheng et al., 2003; Haller et al., 1997; Pu et al., 2005; Rodríguez-Iturbe et al., 2002). 
A differential susceptibility to vascular injury from malignant hypertension was 
observed in this model (Kantachuvesiri et al., 2001). Despite the same level of 
hypertension and circulating hormonal levels histological evidence of malignant 
hypertension was primarily observed in mesentery and heart.  Hypertensive vascular 
injury in the kidney was observed at a later stage. Medial thickening of vessel walls 
of the interlobular and arcuate arteries was observed after 7 days of induction with 
0.3% I3C (Kantachuvesiri et al., 2001). Conversely after 10 days of induction with 
0.3% I3C the renal pathological changes primarily consist of inflammation and 
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cellular proliferation in the cortical vessels and tubulointerstitium such as myointimal 
hyperplasia and tubular dilation, glomerulosclerosis, along with tubulointerstitial 
inflammation and proliferation (Graciano et al., 2007). These morphological changes 
together with vasoconstriction of preglomerular arteries protect the glomeruli from 
transmission of elevated arterial pressure and maintain normal renal haemodynamics 
(Opay et al., 2006;  Petterson et al., 2005).  However prolonged induction for 14 
days caused more severe hypertensive vascular damage such as fibrinoid necrosis, 
endarteritis obliterans of interlobular arteries and afferent arterioles (Kantachuvesiri 
et al., 2001). This severe vascular damage may result in a marked decline in renal 
haemodynamic function (Liu et al., 2009). Thus renal vascular and interstitial 
inflammatory changes occur during and contribute importantly to the development of 
ANG II-dependent malignant hypertension in Cyp1a1-mRen2 transgenic rats. 
 
1.6.3.3 Salt sensitivity 
 
The hypertensive phenotype following induction is characterized by unaltered renal 
haemodynamics (Opay et al., 2006; Patterson et al., 2005) although in some studies a 
significant decrease in RPF is reported (Mitchell et al., 2006). This indicates that 
Cyp1a1-mRen2 rats with malignant hypertension exhibit a marked increase in RVR 
and preglomerular vascular resistance preventing the transmission of systemic 
hypertension to the glomerular capillaries. Since GFR is not changed, there might be 
a role of enhanced tubular reabsorption in the maintenance of hypertensive 
phenotypes. However urinary sodium excretion was not markedly altered in Cyp1a1-
mRen2 rats after induction (Mitchell et al., 2006). Thus they have an impaired 
pressure natriuretic response to the increased arterial blood pressure. The kidney’s 
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inability to maintain sodium excretion in this hypertensive rat model was examined 
by salt loading experiments. Feeding a low-salt diet (0.04%) substantially attenuated 
the development of hypertension and feeding a high-salt (8%) diet exacerbated the 
course of hypertension (Husková et al., 2010). Moreover short-term activation of the 
Cyp1a1-mRen2 transgene induces salt-sensitive hypertension in these transgenic rats 
similar to the salt-sensitive hypertension developed after short-term exposure to 
intravenous ANG ΙΙ (Howard et al., 2005). The blood pressure returns to normal 
within 10 days after the cessation of I3C induction. Subsequently feeding these 
animals with a high salt diet (8.0% NaCl) caused a significant increase in blood 
pressure. The absence of any significant change in either GFR or RPF during the 
development of this salt-sensitive hypertension suggests the contributory role of 
enhanced tubular reabsorption. It might be possible that enhanced tubular 
reabsorption developed during transient induction of ANG II-dependent hypertension 
leads to an impaired ability of the kidney to respond to elevated salt intake and thus 













1.7 Aims of the study 
 
Inappropriate activation of the renin angiotensin system (RAS) is a major factor 
contributing to the development of hypertension. The synergistic action of ANG ΙΙ 
on renal haemodynamics and tubular transport plays a key role in the development of 
ANG ΙΙ-dependent hypertension. Accordingly the first aim of the present study was 
to characterize renal haemodynamics and renal sodium handling during the 
development of ANG ΙΙ-dependent hypertension in the Cyp1a1-mRen2.F transgenic 
rat. 
 
Several studies have demonstrated that ANG ΙΙ stimulates the proximal and distal 
tubular sodium reabsorption rate. Although most of the filtered load is reabsorbed in 
the proximal tubule, sodium reabsorption in the distal tubule and cortical collecting 
duct is very critical because the fine-tuning of sodium reabsorption occurs in this 
region. Thus the second aim of the study was to identify the activity of the distal 





























All experiments described were performed in accordance with the Home Office 
Animals (Scientific Procedures) Act 1986. All transgenic rats used in this experiment 
were bred at the animal facility in the University of Edinburgh. For control purposes 
male Fischer rats (F344) were bought commercially (Harlan, UK).  All rats were 
given free access to water and standard commercial rat chow (Special Diet Services, 
Witham, Essex, UK) and maintained under controlled conditions of temperature 
(21±1Ο C) and humidity (50±10%) and a light/dark cycle of 12hr.  
 
2.2 Induction of transgene 
 
The Cyp1a1-mRen2 transgene was induced by indole 3 carbinol (I3C, Sigma-
Aldrich, UK) at the rate of 100mg/kg body weight. I3C was finely powdered by 
using a mortar and pestle and suspended in vegetable oil (50mg/ml). I3C 
administration was carried out daily by gastric gavage at 11am for either 1-day, 3-
days or 7-days. Control rats received vegetable oil only (200µl/100gm). During this 
induction animals had free access to food and water.  
 
2.3 Surgical protocols 
 
For the renal function experiments, the rats (250-300 gm) were anaesthetized by 
intraperitoneal injection of Inactin (Thiobutabarbital, Sigma, Poole, Dorset, UK; 
100mg/kg, IP) and placed on a thermostatically-controlled surgical table to maintain 
body temperature at 37ºC. A small incision was made over the left jugular vein and 
then the vessel was separated from the connecting tissue. Once the left jugular vein 
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was prepared for cannulation, a small puncture was made and cannulated with 
polyethylene tubing (PE50, Portex fine bore polythene tubing, Jencons, UK) 
connected with a 5ml syringe containing 0.154M NaCl. This route was used to allow 
intravenous infusion of solutions and additional doses of anaesthetic (if required). 
The right carotid artery was similarly cannulated by PE50 tubing connected with a 
20ml syringe containing heparin solution (40 units per ml; Fluka, UK). A 
tracheotomy was performed to maintain a clear airway. A supra-pubic incision was 
made and the bladder was exposed by blunt dissection through the abdominal wall. 
The bladder was catheterised with PE-90 tubing to allow timed urine collections to 
be made. Deknatel silk 5.0 (Teleflex Medical, NC, USA) was used as surgical suture 
during the experiment. At the end of surgery, the jugular catheter was connected to a 
syringe pump (AL2000 model, World Precision instruments, Sarasota, FL, USA) for 
a continuous infusion of infusate solution (120mM NaCl, 10mM NaHCO3, 5mM 
KCl, 15 mM LiCl, pH 7.4) containing 0.5% Inulin-FITC (Fluorescence 
Isothiocyanate; Sigma-Aldrich, UK) and 1% p-aminohippuric acid (Sigma-Aldrich, 
UK) at a rate of 1ml/hour/100gm body weight. The arterial cannula was connected to 
a blood pressure transducer (Powerlab, ADinstruments Ltd, Chalgrove Oxfordshire, 









2.4 Renal clearance infusion protocol 
 
Following surgery, rats were infused intravenously (1ml/100g BWt/hr) with the 
infusate described earlier and allowed to stabilise for one hour. Following 
stabilisation, a small blood sample was collected (approximately 75µl) into two 
heparinised capillary tubes (Hawksley, Lancing, Sussex.UK). Immediately after 
collection, the capillary tubes were spun in a haematospin 1400 centrifuge 
(Hawksley, Lancing, Sussex, UK) and the plasma was stored at -20°C following 
haematocrit measurement. For the next 40 minutes a urine collection tube with a 
known volume of mineral oil (to stop evaporation) was placed at the end of the 
bladder catheter for continuous urine collection. After this, the first urine collection 
tube was removed and a second blood sample taken as before. At this point a bolus 
dose of amiloride (2mg/kg Bwt; vehicle= 2% DMSO in infusate solution, 
50µl/100gm) was given via the vein and amiloride (Sigma-Aldrich, UK) also added 
to the infusate (2mg/kg Bwt/h) to block ENaC. A second urine collection tube was 
attached and urine collected for another 40 minutes. As before, after this 40 minute 
period the urine collection tube was removed and a small blood sample was 
collected. Following this, a bolus of amiloride plus thiazide (2mg/kg Bwt vehicle= 
2% DMSO in infusate solution, 50µl/100gm; Sigma-Aldrich, UK) was given and 
both diuretics were also added to the infusate (2mg/kg Bwt/h). Thus both ENaC and 
NCC were blocked during this urine collection period. A final (U3) urine collection 
was then made as before. 
 
To confirm the stability of renal function during this protocol and any effect of the 
DMSO vehicle, a time-control experiment was performed. In the time control 
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experiment only vehicle was added with infusate followed by a bolus injection of 
vehicle only. Urine and blood samples were collected as described earlier.  
 
At the end of the experiment terminal blood (2ml) was collected in heparinised tubes 
(Sarstedt AG and Co, Numbrecht, Germany) and centrifuged for 5 minutes at 16000 
g to separate plasma and stored at -20°C. The animal was then sacrificed by over 
dose of anaesthetic and the kidneys, heart adrenals and lung were collected on dry ice 
and stored immediately at -70°C for further analysis. A schematic diagram of the 














Figure. 2.1 Infusion protocol for clearance study. (A) Time control experiment, (B) Distal tubular 
function study. 
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2.5 Tail cuff plethysmography measurement of blood 
pressure 
 
Systolic blood pressure (SBP) was measured using tail cuff plethysmography (tail 
cuff) in conscious, restrained rats (Harvard Apparatus, Edenbridge, Kent, U.K.). At 
the beginning, rats were conditioned to the tail cuff restraint and the warming 
chamber for 10-20 min/day for at least 5 days. Once a stable reading was obtained 
rats were considered trained and ready for the experiment. The tail cuff measures the 
systolic blood pressure by sensing the changes in the blood flow in the rat’s tail via 
an optical transducer inside the cuff. Rats are placed in a heating box and warmed to 
around 30°C to dilate the tail artery and allow sufficient blood flow into the tail. At 
this point the pre-heated rat is placed inside the tail cuff restraint and a cuff was fitted 
on the tail. The cuff was then inflated by automatic pump, the optical transducer 
measures the pressure at which the blood vessel is occluded and blood flow stopped 
i.e. the SBP in mmHg. The data measured are amplified and viewed on a PC via a 
serial link, where the data are recorded from the tail cuff. A total of eight readings 
are taken for each measurement, four of which are on cuff inflation and four on the 
cuff deflation. A record is made of the four deflation values and the mean of these 
calculated as systolic blood pressure. The inflate values were rejected as they were 
usually inaccurate due to the rat reacting with movement as the cuff tightening 
around its tail. At least two consecutive readings were taken for each animal. 
However in one experiment (Figure 3-5.A) another tail cuff device (IITC Life 
Science, Woodland Hills, CA, USA) was used to measure mean blood pressure 
instead of SBP using the similar method.  
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2.6 Metabolic cage study 
 
To measure fluid and electrolyte balance in conscious animals, a group of 8 
transgenic rats were housed individually in metabolism cages (Techniplast, Italy) 
which were provided with stainless steel mesh bottoms and a urine collection pan 
underneath attached to a glass collection tube. Rats were kept under controlled 
conditions of temperature (21±1°C) and humidity (50±10%) and a light/dark cycle of 
12hr. Animals had free access to powdered RM1 diet (0.3% sodium) and water. The 
first 3 days were considered as an acclimatization period and no data were recorded 
during that time. After that period, daily food consumption, water intake, urinary and 
faecal excretion and body weight were measured for three days of baseline recording. 
All the measurements were recorded at 10.00am±1 hour to avoid any effect of time. 
After daily collection animals were placed into a cleaned cage for the next collection. 
After baseline collection, animals received I3C by daily gavage for 7 days, during 
which measurements were made as before. Urine and faeces were stored at -4°C until 









2.7 Dietary restriction of sodium 
 
A group of transgenic rats (n=5) were prepared for measurement of SBP by the tail 
cuff method as described. After training, baseline SBP was measured for 3 
consecutive days. Then animals were transferred to a clean home cage and fed low-
sodium diet (0.03% sodium; Special Diet services, UK) for the rest of the study 
period. Following the 3 days of acclimatization to low sodium diet, SBP was again 
measured for another three consecutive days. After this animals were induced by 
daily gavage for seven days; SBP was measured daily during this period. At the end 
of the 7 days of induction renal function was measured as described above (section 
2.3 & 2.4). A schematic diagram of the experimental regime for this experiment is 













Figure 2.2: Experimental regime for dietary sodium restriction study. 
 
 
 Induction with I3C 
SBP measurement  









On low Na 
3 days 
Low Na Normal Na 
 70 
2.8 Chronic inhibition of sodium chloride cotransporter 
 
2.8.1 Baseline SBP measurement 
 
A group of transgenic rats (n=6) maintained on standard rat chow were trained for 
measurement of SBP by tail cuff as described above. A baseline measurement was 
recorded over three consecutive days. 
 
2.8.2 Minipump implantation 
 
Following baseline measurement, the rats underwent surgery for subcutaneous 
implantation of an osmotic minipump (model 2ML1; ALZET, Cupertino, CA, USA). 
The pumps delivered hydrochlorothiazide (Sigma-Aldrich, UK; 4mg/kg/day in 1:1 
DMSO:saline) and were primed overnight in 0.154M NaCl saline. For minipump 
implantation the animals were anaesthetized with isoflurane gas (2-3%) plus oxygen 
(0.4-0.5lit/min) and I.V. buprenorphine as an analgesic (Vetergesic, Pfizer, at 
0.01ml/g body weight). The skin over the implantation site was shaved and washed. 
A 1 cm incision was made on the back and a haemostat was inserted into the incision 
to create a pocket for the pump into which a pump was inserted. The wound was 
closed with wound clips (Clay Adams, BD, NJ, USA) and the rats were placed into a 
heated recovery box until they regain consciousness. The rats were returned to their 





2.8.3 Induction and SBP measurement 
 
Animals were allowed 24h for recovery from the effect of surgery before SBP was 
measured again for 3-4 days.  The animals then received I3C by daily gavage for 3 
days and SBP was measured during this period. At the end of induction renal 
function was measured as described (section 2.3 and 2.4). A schematic diagram of 
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2.9 Chronic Inhibition of Mineralocorticoid Receptor 
 
2.9.1 Baseline SBP measurement 
 
A group of transgenic rats (n=6) maintained on standard rat chow were trained for 
measurement of SBP by tail cuff as described (section 2.5). A baseline measurement 
was recorded for three consecutive days. 
 
2.9.2 Minipump implantation 
 
Following baseline measurement, the animals underwent surgery for subcutaneous 
implantation of an osmotic minipump (model 2ML1). The pumps had been primed 
overnight to continuously administer spirolactone (Sigma-Aldrich, UK) at 
20mg/kg/day (Macdonald et al., 2000). Spirolactone was dissolved in 50% 
polyethylene glycol and the minipump was implanted as described (section 2.8.2). 
 
2.9.3 Induction and SBP measurement 
 
Animals were allowed 24h for recovery from the effect of surgery before SBP was 
measured daily over 3-4 days.  The animals then received I3C by daily gavage for 3 
days and SBP was measured daily over this period. At the end of induction renal 





Figure 2.4: Experimental regime for MR antagonism study 
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2.10 Chronic inhibition of AT1 receptor 
 
A cohort of transgenic animals (n=6) was housed singly in normal cages and allowed 
free access to water and standard rat chow. Animals were trained for tail cuff SBP 
measurement as described above. Three consecutive readings of daily SBP were 
recorded as a baseline measurement. During this period, daily drinking rate was 
monitored by weighing the water bottle. The AT1 receptor antagonist losartan (Fluka 
Analytical, Sigma-Aldrich, UK) was then added to the drinking water at a 
concentration designed to give a daily intake of 10mg/kg/day.  The losartan-
containing water was replenished daily. SBP was measured daily by tail cuff 
plethysmography as described (section 2.5) for 3 days of losartan treatment before 
the rats were induced with I3C for a further 3 days. At the end of induction renal 
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2.11 Measurement of Glomerular Filtration Rate (GFR)  
 
Glomerular filtration rate (GFR) was calculated by the clearance of FITC-inulin as 
detailed  (Lorenz, 2002) using the following equation:   
GFR = UInuV / PInu     
where UInu = Inulin concentration in urine, PInu = Inulin concentration in Plasma and 
V = urine flow rate.  
 
Urine samples were diluted at a 1:100 ratio in HEPES buffer (pH 7.4; Sigma-
Aldrich, UK) as the fluorescence of FITC is pH-sensitive. Then 5µl of pre-diluted 
urine, plasma and standards (ranging from zero to 1mg/ml) were added with 195µl of 
HEPES to a black 96 well plate (Microfluor Solid Microplate, Nunc, Thermo 
Scientific). FITC-inulin concentration in urine and plasma were measured by 
fluorescence with excitation at 485nm and emission at 538nm by using a Wallac 
multilabel counter (model 1420; Perkin Elmer, Waltham, Massachusetts, USA). 
 
2.12 Measurement of Renal Plasma Flow (RPF) 
 
RPF was measured by the clearance of PAH and calculated using the following 
equation  
RPF = UPAHV / PPAH  
where UPAH = PAH concentration in urine, PPAH = PAH concentration in plasma and 
V = urine flow rate.  
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The concentration of PAH was measured by using following method. Plasma 
samples were diluted with 3.2% trichloroacetic acid (TCA; Sigma-Aldrich, UK) at 
1:20 dilution and vortexed briefly. A 10 minute equilibration at room temperature 
was followed by a second vortex mixing and another (5 minutes) incubation. 
Samples were then centrifuged (3 minutes at 16,000g). 500µl of supernatant was 
directly transferred to an eppendorf tube. Urine was diluted in 3.2% TCA (1:8000) 
and 500µl of the urine sample were taken. 25µl of each standard were taken in 
duplicate to eppendorf tubes ranging from zero to 1mg/ml and then diluted at a 1:20 
ratio by adding 475µl of TCA. 100µl of 0.2N HCl solution and 50µl of 0.1% NaNO2 
(Sigma-Aldrich, UK) were added to all plasma, urine and standard samples which 
were vortexed and left for 2-3 minutes. After that 50µl of 0.5% ammonium sulfamate 
(Sigma-Aldrich, UK) was added and mixed by brief vortex. Finally 50µl of 0.1% N-
(napthyl) ethylenediamide dihydrochloride (Sigma-Aldrich, UK) was added and 
mixed by vortex. The tubes were incubated at room temperature for between 15 min 
to 1hour to allow colour development. Colorimetric measurement was taken in 
spectrophotometer (Wallac 1420 Multilable HTS counter, model 1420; Perkin Elmer, 
Waltham, Massachusetts, USA) at 545nm. Concentrations were calculated from a 
standard curve.  
 
2.13 Electrolyte and osmolarity measurement 
 
2.13.1 Plasma and Urinary electrolyte measurement 
Plasma sodium, potassium and lithium concentrations were measured by ISE 
electrolyte analyzer (Electrolyte analyzer 9180, Roche, UK) and urinary electrolytes 
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were analyzed by flame photometer (BWB Technologies, Essex, UK) following a 50 
fold dilution in diluent (1% w/v Brij35, BWB Technologies, Essex, UK). 
 
2.13.2 Faecal electrolyte measurement 
 
Faeces collected during the metabolic cage study were heated at 100°C until constant 
weight was obtained. Dried faeces were then dissolved in 30ml of 0.7 M HNO3 and 
homogenized with a homogenizer (Ultra Turrax, Model T20, Janke & Kunkel, 
Germany). After gentle shaking for the next 24h, samples were briefly spun and 
electrolytes were measured in the supernatant sample by flame photometer (BWB 
Technologies, Essex, UK).     
 
2.13.3 Plasma and Urinary osmolarity measurement 
Plasma and urine (20µl) osmolarity was measured through freezing point depression 
method by using a commercially available instrument (Vogel OM801, Germany).  
 
2.14 Urinary Aldosterone measurement 
 
Urinary aldosterone concentration was measured by ELISA analysis as described 
below (Al-Dujaili et al., 2009). 
 
2.14.1 Assay reagents 
 
Anti-aldosterone antibodies were raised in sheep (Al-Dujaili et al., 1981) and diluted 
in the ratio of 1:100,000 for use. HRP–Donkey-anti-sheep IgG enzyme conjugate was 
prepared in our laboratory following the Lightning-Link HRP technique (Innova 
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Biosciences, Cambridge) and used at the dilution of 1:2000 to develop the ELISA 
method.  Aldosterone standard (Sigma–Aldrich, Poole, England) and aldosterone–BSA 




Assay buffer: 50 mmol/l phosphate buffered saline (PBS) pH 7.4 containing 0.1% 
bovine serum albumin (BSA, Sigma–Aldrich, UK).  
Blocking buffer: 25 mmol/l PBS pH 7.4 containing 0.5% BSA.  
Coating buffer: 25 mmol/l PBS pH 7.4. 
Wash buffer: 15 mmol/l PBS pH 7.4 containing 0.05% Tween 20 (Sigma–Aldrich).  
Substrate buffer: 200 mmol/l acetate/citrate buffer pH 4.2.  
Stop solution: 1 mol/l sulphuric acid in distilled water. 
Substrate solution: 11ml of substrate buffer+300ul substrate mix (10mg/ml 
Tetramethylbenzadine [Sigma–Aldrich, UK] in DMSO)+ 60ul H2O2 (Sigma–Aldrich, 
UK) 
 
2.14.3 Urine extraction of aldosterone 
 
Aldosterone was extracted from urine collected from the metabolic cage study 
described above. 0.5ml of urine was taken in a glass-stoppered tube and then 
aldosterone was extracted with 10 ml dichloromethane (Fisher Scientific, Leicester, 
UK) by vortex. Resultant extract was washed successively with 1 ml aliquots of 0.05 
M NaOH, 0.05 M HCl and distilled water. The solvent was then dried at 40°C and 
the residue was reconstituted by adding 0.5 ml assay buffer. 
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2.14.4 Aldosterone ELISA Assays 
 
96 well ELISA plates (Griener Bio-One, Germany) were coated with aldosterone–3-
CMO-BSA conjugate (200 µl coating buffer containing 0.2 g conjugate/ml 
[Steraloids, USA]). The plates were then left overnight at 4°C covered with film. The 
coating solution was discarded and plates were washed three times with 250 µl wash 
buffer. Plates were then blocked by adding 200 µl blocking buffer and left at 37°C 
for 1h for incubation. Next the blocking buffer was discarded and plates were blotted 
and dried in air. Then 50 µl of urine extracts and aldosterone standards (range from 
0–100 nM) were added to the wells followed by 100 µl of aldosterone antibody 
solution. Plates were then left for 2h at room temperature for incubation. At the end 
of the incubation the contents were discarded and the plate washed with buffer as 
before. Next 100 µl of HRP–anti-sheep enzyme conjugate was added to each well 
and the plates were covered and left for 1h at room temperature for incubation. Plates 
were emptied and washed as before and then after adding 100 µl substrate solution 
plates were left for 15 minutes in dark at room temperature. Finally, 50 µl of stop 
solution was added and absorbance was read at 450 nm in an MRX plate reader 
(Dynatech MRX, Dynatech. Laboratories, Billingshurst, UK).  
 
2.14.5 Calculation of results  
 
Aldosterone concentration in the sample was calculated by using the semi-log cubic 
spline software data reduction method built into the MRX ELISA reader (MRX 
EndPointSoftware ver. 1.33). After taking account of urine volume, values are then 
expressed as pmole/day ± SE.  
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2.15 Urinary albumin Measurement 
 
Rat urine albumin measurements were determined using a commercial Microalbumin 
Kit (Olympus Diagnostics Ltd, Watford, UK) adapted for use on a Cobas Fara 
centrifugal analyser (Roche Diagnostics Ltd, Welwyn Garden City, UK).  The 
immunoturbidimetric assay was standardised against purified albumin standards 
(Sigma Chemical Co. Poole, UK) with samples diluted in phosphate buffered saline 
as appropriate. 
 
2.16 Protein Abundance measurements 
 
2.16.1 Kidney homogenization 
 
Initially during the optimization of Western blot analysis, two different lysis buffers 
were tried to extract the protein from whole kidney sample. The first buffer (buffer 1) 
was composed of 20mM HEPES (pH 7.4), 5mM EDTA, 5mM Na2P4O7, 1%  triton 
x-100, 1mM NaV, 10mM NaF, 1% protease inhibitor cocktail. The second lysis 
buffer was composed of 250mM sucrose (BDH, Poole, UK), 10mM triethanolamine 
(BDH, Poole, UK), 2% protease inhibitor cocktail (Pierce Protein Research Product, 
Thermo Scientific) and pH was adjusted to 7.6. As expected extraction was obtained 
with lysis buffer 2, this buffer was used to extract protein for the experiment using 
the following method. Stored kidneys were thawed at 4°C and then placed in ice-cold 
lysis buffer (10ml/gm kidney). Kidneys were homogenized by using a 
homogenization drill (T-25 digital, ULTRA –TURRAX, IKA, Werke GmbH & Co, 
Germany). Homogenization was carried out in a random order to avoid any bias 
resulting from protein degradation. After proper homogenization the tubes were left 
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on ice for 15 minutes as this was shown to give better extraction of protein. 
Homogenates were then centrifuged at 1000g for 5 minute at 4°C to separate debris. 
The supernatant was aliquoted and stored at -20°C. A sample was taken to determine 
the protein content by BCA protein assay. 
 
2.16.2 Determination of protein content 
 
Protein samples were diluted 100 times in deionised water. Bovine serum albumin 
(BSA) standards were prepared from the 2.0 mg/ml stock solution provided with the 
assay kit (The Thermo Scientific, Pierce BCA Protein Assay Kit). 40µl of each 
standard and sample were taken into a test tube and 800µl of the working reagent (50:1, 
reagent A:B, provided with assay kit) was added to each tube and mixed well. Tubes 
were incubated for 30 minutes at 60°C in a water bath and then cooled to room 
temperature. Now the spectrophotometer (Utrospec 2000, Pharmacia Biotech, 
Cambridge, UK) set to 562 nm, was zeroed on a cuvette filled only with water. 
Subsequently, the absorbance at 562 nm was measured for all the samples within 10 
minutes. The average 562 nm absorbance measurement of the blank standard (water 
only) replicates was subtracted from the 562 nm absorbance measurement of all other 
individual standard and unknown sample replicates. A standard curve was prepared by 
plotting the average blank-corrected 562 nm measurements for each BSA standard 
against concentration (μg/ml). The standard curve was used to determine the protein 








2.16.3 SDS-polyacrylamide gel electrophoresis 
 
2.16.3.1 Gel Preparation 
 
A Bio-Rad mini cell system (Bio-Rad Laboratories, Hercules, CA, USA) was used to 
prepare gels for protein electrophoresis. Glass plates and spacer plates were rinsed 
with 70% ethanol and left to dry before being assembled in the gel casting frame. A 
sufficient amount of 10% polyacrylamide running gel was prepared (0.375M Tris-Cl 
[1.5M Tris-Cl pH 8.8; Sigma-Aldrich, UK], 0.1% SDS [sodium dodecyl sulphate; 
Sigma-Aldrich, UK], 10% acrylamide [Bio-Rad Laboratories, Hercules, CA, USA], 
TEMED [0.05% tetramethylethylenediamine; Sigma-Aldrich, UK]) and freshly 
prepared APS (0.067% ammonium peroxy disulphate; Sigma-Aldrich, UK) were 
added immediately before use to cause gel polymerization. The solution was then 
poured between the glass plates and water saturated butanol was added to create a 
flat transition front. After this, the running gel was left 15-30 minutes to set at room 
temperature. In the meantime, a 4% stacking gel was prepared (0.12 M Tris-Cl [1.5M 
Tris-Cl PH 6.8], 0.1% SDS, 4% Acrylamide, 0.05% APS and .067% TEMED).  
 
Once the above mentioned running gel was set, the butanol was poured off followed 
by a rinse with deionized water. The stacking gel (~5 ml) was then poured onto the 
running gel and a comb was inserted immediately. At this point the stacking gel was 
left for 15 minutes to set at room temperature. The gel was then fitted with gel tank 
(Mini PROTEAN 3 Cell, Bio-Rad Laboratories, Hercules, CA, USA) and immersed 
in buffer. The comb was removed and the wells were flushed out thoroughly with 
running buffer (0.025M Tris, 0.1% SDS, 0.192M glycine in deionised water). 
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2.16.3.2 Sample preparation and loading 
 
Samples were taken out from -20°C and thawed on ice. An appropriate amount of 
protein sample containing 50µg of total protein was taken in a fresh eppendorf tube. 
Now 4µl of 5X laemmli buffer (for 1X, 2% SDS, 50mM Tris, 0.01% bromophenol 
blue, 10% glycerol) and 1µl of 2M DTT was added and then deionised water was 
added to make a final volume of 20µl. Samples were mixed and heated at 60°C for 
10 minutes. The wells were then loaded with 20µl of sample by using gel loader tips 
(Eppendorf, UK). 5µl of rainbow marker (Fermentas Life Science) and 5µl Cruz 
marker (Santa Cruz Biotechnology) were also loaded in two separate wells randomly 
to identify the molecular weight of bands. The gels were run at a constant voltage of 
150 V for 60 minutes. Separation of coloured protein markers confirmed 
electrophoresis was a success.  
 
2.16.3.3 Membrane Transfer 
 
PVDF membrane (Amersham Biosciences) and blotting paper (Bio-Rad 
Laboratories, Hercules, CA, USA) of appropriate size (cut to the dimensions of the 
gel, approximately 6x9 cm) were prepared in advance. PVDV membrane was 
submerged in methanol and blotting paper in transfer buffer. After 5/10 minutes the 
membrane was taken out from methanol and submersed in transfer buffer.   
Complete wetting of the membrane is important to ensure proper binding of proteins. 
Once the proteins were separated the glass plates were taken out carefully and 
immersed into transfer buffer. The gel was then carefully taken out from the glass 
plates and the stacking gel was stripped off from the running gel. This equilibration 
of gel in transfer buffer helps facilitate the removal of electrophoresis buffer salts and 
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detergents. Moreover equilibration allows the gel to adjust to its final size prior to 
electrophoretic transfer. Now one of the pre-soaked sheets of blotting paper was 
placed onto the platinum anode.  Then all air bubbles were excluded by rolling a 
pipette over the surface of the blotting paper. Subsequently, the pre-wetted PVDF 
membrane was placed on top of the wetted blotting paper and the air bubbles rolled 
out as before. Now the equilibrated gel was placed on top of the PVDF membrane, 
aligning the stack as perfectly as possible. Finally another piece of pre-soaked 
blotting paper was placed on top of the gel. Air bubbles were removed from between 
the gel and filter paper. Once this gel/PVDF stack was complete it was placed onto a 
semi-dry transfer unit (Trans-Blot SD, Bio-Rad Laboratories, Hercules, CA, USA) at 




Once the transfer was completed the membrane was blocked in 20 ml of either 5% 
dried skimmed milk (Marvel, Premier Brands UK Limited, Spalding, Lincolnshire) 
or 3% BSA (BDH, Poole, UK) in TBS Tween (20mM Tris-Cl [0.2 M Tris-Cl, pH 
7.6], 137mM Sodium Chloride, 0.1% Tween 20 [Polyoxyethylenesorbitan 
monolaurate, BDH, Poole, UK]) for 1 hour at room temperature on a platform shaker 
(Stuart Scientific, Staffordshire, UK) at the speed of 40unit. At the end of blocking, 
5ml of blocking solution was taken in a universal tube and an appropriate amount of 
primary antibody was added (Primary antibody dilutions are given below). Now the 
membrane was rolled into a 50 ml Falcon tube and left overnight at 4°C. The 
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remaining blocking solution was kept at 4°C to use during probing with secondary 
antibody. 
 
The overnight-probed membrane was washed 3 times (5 minutes each) in TBS 
Tween using platform shaker at the speed of 60 rev/min. Then peroxidase conjugated 
secondary antibody (Santa Cruz Biotechnology, Heidelberg, Germany) was added 
with blocking solution (1:10000 dilution) in a Falcon tube.  Then the membrane was 
rolled into the tube carefully and incubated for 1 hour at room temperature on an 
orbital shaker (Stuart Scientific, Staffordshire, UK). After the incubation, membrane 
was washed 3 times as described earlier. The membrane was then incubated with an 
ECL-plus Western blotting detection system (Thermo Scientific, IL, USA) following 
the manufacturer’s instructions. Excess ECL substrate from the membrane was 
removed by putting the membrane over a piece of folded tissue paper and briefly 
touching the edge of the membrane to the paper. Then the membrane was placed 
down on thin plastic, the bubbles were removed and the membrane was wrapped 
completely. The membrane was taped inside a film cassette and exposed to a 
photographic film (BioMax XAR Film, Kodak, Sigma-Aldrich, UK) for an adequate 
exposure time. The film was developed and immunoreactivity was quantified by 
densitometry by using ImageJ (Abramoff et al., 2004). 
 
2.16.4 Antibody source and dilutions 
 
Initially polyclonal rabbit anti-rat NCC was purchased from Alpha Diagnostics (San 
Antonio, TX, USA), but due to very strong background noise, polyclonal anti-NCC 
from Chemicon (Millipore, MA, USA) was used. For α-ENaC, polyclonal antibody 
raised against rat α-ENaC produced in rabbit was purchased from Upstate (NY, 
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USA). Polyclonal Sgk-1 rabit anti-Sgk-1 was purchased from Upstate (NY, USA). 
For nedd4, antibody raised in rabbit was purchased from Upstate (NY, USA). 
NKCC1 specific antibodies N1 and T4 (also binds with NKCC2) were a gift from 
Dr. Peter W Flatman. Goat anti rabbit Immunoglobulins conjugated with horseradish 
peroxidase purchased from Promega, UK was used as secondary antibody. Optimum 
dilutions for primary and secondary antibody are shown in the below table. 
 
Protein Name Primary antibody dilution Secondary antibody dilution 
T4 1:10000 1:10,000 
N1 1:5000 1:10,000 
NCC 1:2500 1:10,000 
α-ENaC 1:2000 1:10,000 
Sgk-1 1:5000 1:10,000 
Nedd4-1 1:5000 1:10,000 
GAPDH 1:5000 1:10,000 
 
2.16.5 Assessment of equal loading  
 
To assess equal loading of protein, GAPDH primary antibody (R&D Systems, UK) 
was used. The Western blot was incubated with GAPDH antibody (1:5000) for 1 
hour at room temperature on an orbital shaker. Following washing, the blot was 
probed with goat anti rabbit secondary antibody for 1 hour at room temperature on an 
orbital shaker. Then membrane was developed following the method described 
above. A protein of 36 KDa size appeared and equal loading was confirmed by 
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Figure 2-6: Representative blot for whole kidney GAPDH protein abundance in Non-Induced (NI, 
n=6), 1-day Induced (1Day, n=6), 3-day Induced (3Day, n=6) and 7-day Induced (7Day, n=6). 
Western blot analysis identified a protein band at approximately 36 kDa (A). Summary of band 
density of 4 groups of rats by densitometry quantification is shown in (B). All groups showed 
similar density levels. 
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2.17 Statistical analysis 
 
Statistical comparisons were made using an unpaired t-test, one-way ANOVA or 
two-way ANOVA as appropriate (Tukey posthoc test) using GraphPad Prism 
software (Graphpad software, San Diego California, USA). Statistical significance 






















































3.1 Renal function in the anaesthetized rat: time 
control study 
 
Time-controlled experiments were conducted to evaluate the stability of the rat’s 
renal function after surgical preparation for renal clearance study. In the present 
study a group of six Fischer rats (Harlan, UK) were prepared surgically for renal 
clearance. Following one hour equilibration, three urine collections, each of which 
was forty minutes, were performed. Renal haemodynamics blood pressure, urine 
flow rate and urinary sodium excretion were measured throughout (a detailed 
protocol is described in figure 2.1A in the methods section). Data obtained in this 
study were used to confirm that any changes observed in the following studies could 
be attributed to the administration of drug rather than being an effect of time or 
vehicle. 
 
3.1.1 Blood pressure and renal haemodynamics 
 
Figure 3-1 shows the mean arterial blood pressure (MABP), glomerular filtration rate 
(GFR) and renal plasma flow (RPF) over three collection periods. The rats had a 
stable blood pressure throughout the experiment, with no significant difference 
between the MABPs recorded in each of the collection periods (Figure 3-1A). 
Similarly there were no significant changes in GFR and RPF throughout the 





Figure 3-1: (A) MABP (B) GFR (C) RPF in Fischer non-induced (N=6) rats during three consecutive 
periods (T1, T2 and T3) of urine collection. Data are mean±SE and statistical comparison was made by one 
way ANOVA. There were no significant differences. 
3.1.2 Urine flow and urinary sodium excretion 
 
Figure 3-2 shows urine flow rate and urinary excretion of sodium. Both urine flow 
rate and urinary sodium excretion were stable throughout the experiment, with no 
significant differences measured in the three collection periods.  
 
These data indicate that the surgical preparation and infusion protocol have no 
significant effect on the rat’s renal haemodynamics, blood pressure, urine flow rate 
and urinary sodium excretion. Consequently, protocols of this duration can be used 
to evaluate the effect of pharmacological intervention on renal function in future 
studies. 
 
 Figure 3-2: (A) Urine Flow Rate (B) Urinary Sodium Exretion in Fischer non-induced (N=6) rats during 
three consecutive periods (T1, T2 and T3) of urine collection. Data are mean±SE and statistical comparison 
was made by one way ANOVA. There were no significant differences. 
 
3.2 Selection of appropriate genetic control group 
 
For control purposes, two groups of rats were used. The first group was non-
transgenic Fischer rats (F344 from Harlan, UK) and the second group was Cyp1a1-
mRen2 transgenic rats on a Fischer 344 background. These rats received vehicle 
(vegetable oil) by gastric gavage for seven days before the experiment started. 
 
3.2.1 Blood pressure and renal haemodynamics 
 
MABP, GFR and RPF for both groups of rats are summarised in Figure 3-3. There 
was no difference in MABP between the two control groups. Both GFR and RPF 
were also comparable between groups. 
 
3.2.2 Urine flow and urinary sodium excretion 
 
Figure 3-4 shows the urinary sodium excretion and urine flow rate for Cyp1a1-
mRen2.F transgenic and non-transgenic control rats. No difference in urinary sodium 
excretion and urine flow rate were observed between the Cyp1a1-mRen2.F 
transgenic and non- transgenic control. Moreover no difference in fractional 
excretion of sodium indicates that tubular sodium sodium reabsorption is also 
comparable between two groups. Plasma electrolytes, plasma osmolarity and urine 







 Non-transgenic rats 
 (n=8) 
Transgenic rats mRen2.F 
(n=8) 
HCT 46.93±0.97 46.5±0.98 
PNa  (mmol/L) 135.7±1.41 135.9±0.51 
PK  (mmol/L) 4.54±0.18 4.43±0.48 
PLi  (mmol/L) 1.29±0.05 1.24±0.04 
POSM (mOSM/Kg) 286±2.73 289±2.83 
UOSM (mOSM/Kg) 1637±81.17 1697±67.32 
 
Table 3.1: Plasma data from both transgenic and non-transgenic control groups. PNa, PK, and PLi are 
the plasma concentration of sodium, potassium and lithium respectively. POSM and UOSM are the 
plasma osmolarity and urine osmolarity respectively. Values are Mean±SE and statistical comparison 




















Figure 3-3: (A) MABP (B) GFR (C) RPF in non-transgenic Fischer control rats (n=8) and Cyp1a1-mRen2.F 
transgenic control rats (mRen2F, n=8). Data are mean±SE and statistical comparison was made by unpaired 




Figure 3-4: (A) Urine flow rate (B) Urinary excretion of sodium (C) Fractional excretion of sodium in non 
transgenic Fischer control rats (n=8) and Cyp1a1-mRen2.F transgenic control rats (mRen2.F, n=8). Data are 
shown as mean±SE and statistical comparison was made by unpaired t test. There were no statistical 
significant differences between two groups. 
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3.3 Effect of Cyp1a1-mRen2 transgene induction on 
renal function 
 
3.3.1 Development of hypertension 
 
I3C (100mg/kg of body weight) was administrated to Cyp1a1-mRen2.F transgenic 
rats by daily gavage for 1, 3 and 7 days. Daily measurement of mean blood pressure 
by tail cuff plethysmography for rats induced for 7 days is shown in figure 3-5A. 
Blood pressure was found to be elevated from the first day of induction and further 
elevation was observed as the experiment progressed. The development of 
hypertension was accompanied by a progressive loss of body weight (Figure 3-5B). 
Body weight was decreased by day three of induction and continued to decrease for 
the rest of the induction period. After 7 days of induction rats lost 10% of body 
weight and also showed symptoms associated with malignant hypertension in 
rodents. Rats were hunched, inactive and had piloerection. These findings are 
consistent with the previous data using this dose of I3C (Liu et al., 2009). At the end 
of the period of induction rats were anaesthetized for MABP measurement and 
analysis of renal function. Direct measurement of MABP by cannulation identified 









 Figure 3-5: (A) Daily measurement of Mean Arterial Blood Pressure by tail cuff plethysmography (N=6) and 
(B) Daily body weight change. C1, C2 and C3 represent the control period without any induction. I1 to I7 
represent the induction from day 1 to 7. Data are mean±SE and statistical comparisons were made by 
repeated measures ANOVA with Tukey's post hoc analysis. *=p<0.05, **=p<0.01 and ***=p<0.001 vs mean 

















3.3.2 Renal haemodynamics 
 
Figure 3-6B shows GFR in the four groups of animals. On average, GFR was higher 
in the 1-day induced group compared to the non-induced group but this difference 
was not statistically significant. However, after 3 days of induction there was a 
significant increase in GFR. This effect was transient; rats having 7 days of induction 
had a GFR comparable to non-induced controls.  
 
Figure 3-6C shows RPF in the four groups of animals. In general, RBF mirrored the 
patterns of GFR, having a tendency to increase in groups induced for 1 day and 3 
days. One-way ANOVA identified an overall significant difference but there was no 
significant difference between any induced groups compared to the non-induced 
group by post hoc analysis. Thus overall GFR and RPF remained unchanged despite 
the markedly elevated MABP followed by induction. 
 
There was an overall statistical significant difference in filtration fraction found by 
one-way ANOVA but post hoc analysis did not show statistical significance between 
any induced group compared to the non-induced group (Figure 3-7A). Since RPF 
was normal even in the face of a markedly elevated blood pressure, these data are 
suggestive of a marked increase in RVR. Indeed no change in renal vascular 
resistance was observed in 1-day and 3-day induced groups but a significant increase 







Figure 3-6: (A) MABP (B) GFR  (C) RPF in non-induced (NI, n=8), 1-day induced (1day, n=9), 3-day 
induced (3day, n=9) and 7-day induced (7day, n=8) group. Data are mean±SE and statistical comparisons 















Figure 3-7: (A) Filtration Fraction (B) Renal Vascular Resistance in non-induced (NI, n=8), 1-day induced 
(1day, n=9), 3-day induced (3day, n=9) and 7-day induced (7day, n=8) group. Data are mean±SE and 
statistical comparisons were made by one way ANOVA with Tukey's post hoc analysis. *=p<0.05, **=p<0.01 








3.3.3 Renal handling of sodium 
 
Absolute sodium excretion (ENa) and fractional excretion of sodium (FENa) are 
shown in figure 3-8. Excretion of sodium was significantly lower in the 1-day and 3-
day induced group compared to the non-induced group. A further incremental drop 
in sodium excretion was found in the 7-day induced group. Similar differences were 
also observed for fractional excretion of sodium. Since FENa normalizes ENa for 
differences in plasma sodium concentration and GFR, these data reflect changes in 
tubular sodium reabsorption.  
 
3.3.4 Renal handling of potassium 
 
Figure 3-9 shows urinary potassium excretion and fractional excretion of potassium. 
Potassium excretion was comparable across all groups with the exception of a 
marked decrease in the 7-day induced group. No significant difference in fractional 
excretion of potassium (Figure 3-9B) indicates that the decrease in potassium 









Figure 3-8: (A) Urinary Excretion of Sodium (B) Fractional Excretion of Sodium in non-induced (NI, n=8), 
1-day induced (1day, n=9), 3-day induced (3day, n=9) and 7-day induced (7day, n=8) groups. Data are 
mean±SE and statistical comparisons were made by one way ANOVA with Tukey's post hoc analysis. 












Figure 3-9: (A) Urinary Excretion of Potassium (B) Fractional Excretion of Potassium non-induced (NI, 
n=8), 1-day induced (1day, n=9), 3-day induced (3day, n=9) and 7-day induced (7day, n=8) groups. Data are 
mean±SE and statistical comparisons were made by one way ANOVA with Tukey's post hoc analysis. 





3.3.5 Renal handling of water 
 
Osmolar excretion and free water clearance are summarised in Figure 3-10.  Osmolar 
excretion remained stable in both 1-day and 3-day induced groups. But a significant 
decrease in osmolar excretion was observed after 7 days of induction. Free water 
clearance mirrored the osmolar excretion and a significant change in free water 
clearance was only observed after 7 days of induction.  
 
Table 3.2: Renal data and plasma electrolytes in Cyp1a1-Ren2 transgenic rats which 
had induced hypertension for 1, 3 or 7 days. The control group received no 
induction. Data are mean±SE and “n” is given in parentheses. Comparisons were 
made using one-way ANOVA (P value shown), with Tukey’s post hoc analysis: 
*=P<0.05, **=P<0.01. FELi indicates the fractional excretion of lithium; V is urine 
flow rate; CNa/CLi is the ratio of the clearances of sodium and lithium; PNa and PK are 











V (µl/min) 9.8±0.7 13.6±3.5 13.2±1.0 9.3±2.0 NS 
FELi (%) 20.1±3.4 40.9±6.2** 38.8±4.9** 7.9±1.8* <0.01 
CNa/CLi 8.4±1.7 3.4±1.2* 3.9±1.4 2.8±1.0* <0.05 
Hct (%) 46.5±1.0 48.3±0.5 48.7±1.0 52.0±1.1** <0.01 
PNa (mmol/l) 135.9±0.4 134.3±0.7 134.0±0.6 130.3±1.7* <0.01 











Figure 3-10: (A) Osmolar Excretion and (B) Free water Clearance in non-induced (NI, n=8), 1-day 
induced (1day, n=9), 3-day induced (3day, n=9) and 7-day induced (7day, n=8) group. Data are mean±SE 









In order to investigate the effect of induction on daily sodium and water balance, a 
metabolic cage study was performed. In this study, following a three-day 
acclimatization period, control measurements were made over a further three days. 
Subsequently rats were induced by daily gastric gavage of I3C for seven consecutive 
days.  
 
3.4.1 Daily Food and water consumption 
 
Daily food and water intake are summarised in figure 3-11. Daily food intake 
measurement identified a trend of decreased appetite for food upon induction. Food 
intake fell from the beginning of induction and it continued to fall up to the end of 
induction. A significant decrease in food intake was observed on day three of 
induction and it continued to decrease during the remaining period of induction. This 
decrease in food intake was accompanied with a progressive loss of body weight 
throughout the induction period. Figure 3-11C shows the daily measurement of body 
weight for 3 days of control period without any induction and during 7 days of 
induction. By the end of 7 days of induction the rats had lost approximately 10% of 
baseline body weight.   
 
Water intake remained comparable with the control period for the first three days of 
induction. From the forth day of induction water intake progressively increased with 




Figure 3-11: Daily measurement of (A) Food Intake, (B) Water Intake and (C) Body weight during 
control period and transgene induction. C1, C2 and C3 represent the control period without any 
induction. I1 toI7 represent the induction from day1 to 7. Data are mean±SE and statistical 
comparisons were made by repeated measures ANOVA with Tukey's post hoc analysis. *=p<0.05, 
**=p<0.01 and ***=p<0.001 vs mean of control period readings.  
* * * ** ** 
 
 
3.4.2 Daily urine flow 
 
Figure 3-12 shows the daily urine flow remained fairly steady up to the second day 
of induction during the metabolic cage study. In parallel with water intake, a trend of 
increased urinary flow was observed after the third day of induction. A significant 
increase was only found after the sixth day of induction. However no significant 
change in water balance was observed during any period of the study (Figure 3-12B). 
This suggests although there was an increased turnover of water, their balance was 
unchanged overall. 
 
3.4.3 Daily urinary excretion of sodium 
 
Daily sodium intake, urinary excretion of sodium and sodium balance are 
summarised in figure 3-13. In previous experiments it was shown that food 
consumption was reduced due to transgene induction. Consequently a reduction in 
sodium intake was also found following induction. This decrease in sodium intake 
was found to be significant only after day 3 of induction and decreased further over 
the remaining period of induction. Although there was a tendency towards an 
increase in urine flow, daily urinary excretion of sodium was found to be reduced 
after induction. This reduction in urinary sodium excretion was found to be 
statistically significant after 3 days of induction. However animals had a positive 
sodium balance throughout the experiment and no change in sodium balance was 








Figure 3-12: Daily measurement of (A) Urine Flow Rate and (B) Water Balance during control 
period and transgene induction. C1, C2 and C3 represent the control period without any 
induction. I1 to I7 represent the induction from day 1 to 7. Data are mean±SE and statistical 
comparisons were made by repeated measures ANOVA with Tukey's post hoc analysis. 
*=p<0.05 vs mean of control period readings.  
 
 
Figure 3-13: Daily measurement of (A) Sodium Intake (B) Sodium Excretion, and (C) Sodium Balance 
during control period and transgene induction. C1, C2 and C3 represent the control period without any 
induction. I1 to I7 represent the induction from day 1 to 7. Data are mean±SE and statistical comparisons 
were made by repeated measures ANOVA with Tukey's post hoc analysis. *=p<0.05, **=p<0.01 and 
***=p<0.001 vs mean of control period readings.  
* ** *** *** *** 
** ** *** *** *** 
 
3.5 Effect of dietary sodium restriction on Cyp1a1-
mRen2 transgene induction.  
 
It has been shown previously that salt-sensitive hypertension develops after transient 
induction of ANG II-dependent hypertension in this transgenic rat model (Howard et 
al., 2005). Earlier in the current study, renal haemodynamics were found to be 
unaltered suggests that enhanced tubular reabsorption might contribute to the 
maintenance of this form of salt-sensitive hypertension. Moreover an increase in 
sodium reabsorption was also observed in the transgenic rats following induction. 
The present study was performed to evaluate the effects of dietary salt restriction on 
the development of ANG II-dependent hypertension in Cyp1a1-mRen2.F transgenic 
rat. It has been hypothesized that, under the conditions of an activated RAAS, salt 
restriction should attenuate the course of hypertension. For the current study a group 
of 5 transgenic rats were maintained on a low sodium diet before and during a 7 day 
period of induction.  
 
3.5.1 Blood pressure 
 
Systolic blood pressure was measured daily by tail cuff plethysmography. As shown 
in figure 3-14 no significant change in blood pressure was observed in non-induced 
Cyp1a1-mRen2.F transgenic rats placed on a low sodium diet. This indicates that 
basal blood pressure is not salt-sensitive in this model. However induction of 
mRen2.F still caused a significant rise in blood pressure despite dietary sodium 
restriction. Although there was a significant increase in the systolic blood pressure of 
rats kept on a low sodium diet, this was blunted compared to rats on a normal sodium 
 
diet (figure 3-15A). The partial rescue of the hypertensive phenotype by dietary 
sodium restriction was also confirmed by direct measurement of arterial blood 







Figure 3-14: Daily measurement of Systolic Blood Pressure by tail cuff plethysmography (n=5). 
C1 to C3 represent the control period without any induction and rats were kept on normal diet. 
L1 to L3 represent the time period when rats were kept on low sodium diet without any 
induction. I1 to I6 represent the induction period from day 1 to 6 when animals were kept on low 
sodium diet. Data are mean±SE and statistical comparisons were made by repeated measures 










Figure 3-15: (A) Comparison of Systolic Blood Pressure by tail cuff plethysmography between rats kept on normal 
sodium diet (Black line) and Low sodium diet (Red line). C1 to C3 represent the control period without any induction 
and I1 to I3 represent the induction period from day 1 to 3. Data are mean±SE and statistical comparisons were made 
by two way ANOVA with Tukey's post hoc analysis. *=p<0.05 and **=p<0.01.  
 
(B) Mean Arterial Blood Pressure of non-induced control (NI, n=8), 7 day induced normal sodium diet (7day, n=8) 
and 7 day induced on low sodium diet (7day+LowNa, n=5) group. Data are mean±SE and statistical comparisons 
were made by one way ANOVA with Tukey's post hoc analysis. *=p<0.05 vs NI group. 
 
3.5.2 Renal haemodynamics 
 
Figure 3-16 shows the GFR, RPF and filtration fraction of non-induced rats, 7-day 
induced rats on a normal sodium diet and 7-day induced rats kept on a low sodium 
diet. There was a tendency of elevation of GFR in 7-day induced rats kept on a low 
sodium diet but this was not statistically significant compare to the non-induced rats. 
RPF was found to be significantly reduced when induction was carried out together 
with dietary sodium restriction. In consequence, filtration fraction was elevated in 
sodium restricted 7-day induced rats.  
 
3.5.3 Urinary sodium excretion 
 
As expected dietary sodium restriction resulted in a further reduction in sodium 
excretion, but this was not statistically different from 7-day induced rats on a normal 
diet (Figure 3-17A). The contribution of ENaC and NCC, to the enhanced sodium 
reabsorption were also measured in this experiment and compared with that of 7 day 
induced data (ENaC and NCC mediated sodium reabsorption is investigated in 
chapter 4). The natriuretic effect of amiloride was comparable between all groups 
(Figure 3-17B).  However the natriuretic effect of thiazide decreased significantly 
from that of 7-day induced rats on normal diet and became comparable with non-
induced group (Figure3-17C). This suggests that the up regulation of NCC mediated 
sodium reabsorption following induction (shown in chapter 4) is normalized by 











Figure 3-16: (A) GFR, (B) RPF, and (C) Filtration Fraction of non-induced control (NI, n=8), 7-day induced 
normal sodium diet (7day, n=8) and 7-day induced on low sodium diet (7day+LowNa,, n=5) group. Data are 
mean±SE and statistical comparisons were made by one way ANOVA with Tukey's post hoc analysis. 










Figure 3-17: (A) Urinary Sodium Excretion (B) ENaC mediated Sodium transport and (C) NCC mediated 
Sodium transport of non-induced control (NI, n=8), 7-day induced normal sodium diet (7day, n=8) and 7-
day induced on low sodium diet (7day+Low Na, n=5) group. Data are mean±SE and statistical comparisons 
were made by one way ANOVA with Tukey's post hoc analysis. *=p<0.05, ***=p<0.01 and ***=p<0.001 








Mechanisms in the development of 











4.1 Contribution of the ENaC and NCC to Cyp1a1-
mRen2 induced hypertension 
 
A sustained increase in sodium reabsorption was observed following transgene 
induction. The studies in this chapter addressed the mechanism responsible for the 
enhanced sodium reabsorption. As renal haemodynamics remained unchanged 
following induction it was hypothesized that an alteration in tubular sodium transport 
was responsible for the increased sodium reabsorption. Sodium is freely filtered 
through the glomerulus, most of the filtered load is reabsorbed along the nephron. 
The majority of filtered load is reabsorbed in the proximal tubule and loop of Henle. 
But the sodium transporting proteins in the distal nephron segments are responsible 
for the fine-tuning of final sodium excretion. Sodium reabsorption in this segment of 
the nephron is mainly mediated through NCC and ENaC. Several studies have shown 
that ANG ΙΙ stimulates the distal sodium transport process by increasing the activity 
of several sodium transporting proteins such as NHE, NCC, ENaC. In the present 
study, ENaC and NCC, two sodium transporting proteins in the aldosterone-sensitive 
distal nephron were targeted to identify their contribution to enhanced sodium 
reabsorption in Cyp1a1-mRen2.F transgenic rat. ENaC and NCC were blocked 
acutely by amiloride and thiazide (described in the Methods section) respectively in 
four different groups of rats. The first group of rats were not induced, the second 
group of rats were induced for 1 days, the third group of rats were induced for 3 days 




4.1.1 Mean arterial blood pressure 
 
Figure 4-1 shows the effect of acute inhibition of ENaC and NCC on MABP in the 
four different groups. In the non-induced group MABP was not affected by acute 
administration of either amiloride or amiloride in combination with thiazide. In rats 
that had been induced for 1 or 7 days, there was a small but significant drop in blood 
pressure was observed following the combined administration of amiloride and 
thiazide. Since no difference was observed after amiloride administration, this 
reduction was attributed to thiazide. Similarly in the 3-day induced group, a 
reduction in blood pressure was observed following inhibition of ENaC and NCC, 
but this change did not reach statistical significance. 
 
4.1.2 Renal haemodynamics 
 
Figure 4-2 shows the change in GFR following acute blockade of ENaC and NCC in 
four different groups of rats. GFR was not affected by acute administration of either 
amiloride or amiloride in combination with thiazide. However an overall significant 
difference in GFR was observed in different induction period. The effect of blocking 
ENaC and NCC on RPF in four different groups are presented in Figure 4-3. 
Similarly, RPF was not affected by acute administration of either amiloride or 
amiloride in combination with thiazide in all four groups of rats. Therefore these data 
suggest that the small drop in blood pressure observed in Figure 4-1 did not influence 
renal function, since the acute administration of amiloride and thiazide had no effect 






























Figure 4-1: Mean Arterial Blood Pressure during 3 different time point of renal clearance study in Non-
induced group (NI, n=8), 1-day induced group (1day, n=9), 3-day induced group (3day, n=9) and 7-day 
induced group (7day, n=8). For each group the red bar represents the measurement without any drug (1st 
time point), the green bar represents the measurement when ENaC was blocked by amiloride (2nd time 
point) and the blue bar represents the measurement when both ENaC and NCC were blocked with 
amiloride and thiazide (3rd time point). Data are mean±SE and statistical comparisons were made by two-
way ANOVA with Bonferroni's post-hoc analysis. **=p<0.01 vs no drug period of respective group. 
Two-way ANOVA 
Induction period p<0.0001  
Drug effect  p<0.0001 































Figure 4-2: Glomerular Filtration Rate during 3 different time point of renal clearance study in Non-
induced group (NI, n=8), 1-day induced group (1day, n=9), 3-day induced group (3day, n=9) and 7-day 
induced group (7day, n=8). For each group the red bar represents the measurement without any drug (1st 
time point), the green bar represents the measurement when ENaC was blocked by amiloride (2nd time 
point) and the blue bar represents the measurement when both ENaC and NCC were blocked with 
amiloride and thiazide (3rd time point). Data are mean±SE and statistical comparisons were made by two-
way ANOVA with Bonferroni's post-hoc analysis. 
Two-way ANOVA 
Induction period p<0.0001  
Drug effect  ns 





























Figure 4-3: Renal Plasma Flow during 3 different time point of renal clearance study in Non-induced 
group (NI, n=8), 1-day induced group (1day, n=9), 3-day induced group (3day, n=9) and 7-day 
induced group (7day, n=8). For each group the red bar represents the measurement without any drug 
(1st time point), the green bar represents the measurement when ENaC was blocked by amiloride (2nd 
time point) and the blue bar represents the measurement when both ENaC and NCC were blocked 
with amiloride and thiazide (3rd time point). Data are mean±SE and statistical comparisons were 
made by two-way ANOVA with Bonferroni's post hoc analysis.  
Two-way ANOVA 
Induction period p<0.05  
Drug effect  ns 
Interaction  ns 
 
 
4.1.3 Renal sodium handling 
 
The effect of amiloride and thiazide on renal sodium excretion is summarised in 
Figure 4-4. Acute blockade of ENaC by amiloride caused a significant increase in 
sodium excretion in all 4 groups of rats. A further significant increase in sodium 
excretion was observed when both ENaC and NCC were blocked simultaneously by 
amiloride and thiazide respectively. Indeed, the effect of thiazide on sodium 
excretion in all the 4 groups of rats was greater than that of amiloride. This is 
consistent with the greater role of NCC in renal sodium reabsorption.  
 
To distinguish the individual effects of amiloride and thiazide, the net effect of each 
drug was calculated by subtraction. The net effect of amiloride on sodium 
(Δamiloride) represents the amount of sodium reabsorbed via ENaC only. Similarly 
Δthiazide represents the amount of sodium transported by NCC. In order to prevent 
downstream compensation by ENaC, sodium reabsorption by NCC was evaluated as 
the difference between the effect of amiloride and amiloride plus thiazide, rather than 
using just thiazide alone. Since this may cause an up regulation of ENaC due to 
increased distal sodium delivery.  
 
Figure 4-5A shows the comparative natriuretic effect of ENaC blockade by amiloride 
in four different groups. ENaC mediated sodium transport was higher in both 1-day 
and 3-day induced groups, however these increases were not statistically significant. 
This indicates that ENaC mediated sodium reabsorption was not responsible for 
increased sodium retention. NCC mediated sodium transport was also stimulated 
following the induction of the Cyp1a1-mRen2 transgene (Figure 4-5B). The 
 
enhanced sodium reabsorption via NCC was found statistically significant in 3-day 
and 7-day induced groups. This implies that an up regulation of NCC occurred 
following induction and this plays a key role in the increased sodium retention 


















Figure 4-4: Urinary Excretion of Sodium during 3 different time point of renal clearance study in Non-
induced group (NI, n=8), 1-day induced group (1day, n=9), 3-day induced group (3day, n=9) and 7-day 
induced group (7day, n=8). For each group the red bar represents the measurement without any drug(1st 
time point), the green bar represents the measurement when ENaC was blocked by amiloride (2nd time 
point) and the blue bar represents the measurement when both ENaC and NCC were blocked with 
amiloride and thiazide (3rd time point). Data are mean±SE and statistical comparisons were made by 
two-way ANOVA with Bonferroni's post hoc analysis. *=p<0.05, **=p<0.01  and ***=p<0.001  vs no 
drug period of respective group. 
Two-way ANOVA 
Induction period ns  
Drug effect  p<0.0001 
Interaction  p<0.05 
 
*** *** ** * 
*** 








Figure 4-5: (A) ENaC mediated sodium transportation and (B) NCC mediated sodium 
transportation in non-induced (NI, n=8), 1-day induced (1day, n=9), 3-day induced (3day, n=9) and 
7-day induced (7day, n=8) group. Data are mean±SE and statistical comparisons were made by one 
way ANOVA with Tukey's post hoc analysis. *=p<0.05 and **=p<0.01 vs NI group. 
 
4.2 Western blot analysis of ENaC and NCC 
 
The main objective of this study was to examine whether the changes observed 
during acute pharmacological blockade were accompanied by similar changes in 
protein abundance. The expression of two transporters, ENaC and NCC were 
determined by semiquantitative assessment of Western blot analysis. In addition, 
expression of Sgk1 and Nedd4 were also studied for their predominant role in the 
regulation of ENaC. 
 
4.2.1 Optimisation of extraction of protein from whole kidney 
 
Initially for Western blot analysis study, whole kidney protein was extracted using 
lysis buffer 1 (see Methods section for detail). A gel was loaded with extracted 
protein samples and the blot was probed with T4 antibody, which recognized both 
NKCC1 and NKCC2. NKCC1 and NKCC2 are the two isoforms of the Na-K-Cl 
cotransporter (NKCC), abundant in the kidney. A single band of approximately 140 
kDa was identified (Figure 4-6A). Subsequently the blot was stripped and re-probed 
with N1 antibody, specific for NKCC1. This antibody identified a protein of similar 
size (Figure 4-6B).  
 
When the membrane was probed with a NCC antibody (Alpha Diagnostic), the 
antibody failed to identify any protein (Figure 4-7A). The same blot was stripped and 
re-probed with N1 antibody. N1 antibody identified NKCC1 at approximately 140 
kDa size (Figure 4-7B). At this point, protein from whole kidney was extracted by 
using a hypotonic lysis buffer without any detergent (buffer 2, see the Methods 
 
section for detail). This time probing with NCC antibody produced a single band at 













































Figure 4-6: (A) Whole kidney protein samples extracted by lysis buffer 1 and probed with 
T4 antibody. (B) Probed with N1 antibody. L indicates molecular Ladder. 
(A) 
(B) 
Figure 4-7: (A) Whole kidney protein samples extracted by lysis buffer 1 and probed with NCC (Alpha 
Diagnostic) antibody. (B) Probed with N1 antibody. (C) Protein samples extracted with lysis buffer 2 and 
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4.2.2 Optimization for the NCC antibody 
 
Western blots developed with the NCC antibody from Alpha Diagnostic had very 
strong background. To reduce this background noise, membranes were blocked with 
BSA instead of skimmed milk and I also tried to probe with a lower concentration of 
secondary antibody. However these approaches failed to reduce the background. At 
this point another NCC antibody (from Chemicon) was used and this antibody 
identified the same size of protein without background noise. (Figure 4-8A) 
 
To confirm the specificity of the Chemicon antibody, extract from HEK cells was 
used as a negative control as they do not express NCC. Figure 4-8B shows that no 
NCC was identified in the HEK cell extract and a single protein was identified in 
whole kidney extract. Whole kidney extract was also run with a positive control, 
ferret red blood cell sample, where NCC was identified at 160 kDa, whilst in the 













































Figure 4-8: (A) Whole kidney protein samples probed with NCC (Chemicon) antibody.(B) HEK cell line 







L Kidney sample 
220KDa 
 
4.2.3 Expression of NCC 
 
The up-regulation of NCC due to transgene induction identified from the 
pharmacological intervention study was supported by Western blotting findings. 
Figure 4-9 shows a representative immunoblot and summary of densitometry 
quantification of the whole kidney NCC of non-induced, 1-day induced, 3-day 
induced and 7-day induced group. The anti-NCC antibody identified a single protein 
at approximately 130 kDa. There was a notable difference in NCC level of induced 
rats compare to non-induced control rats. A significant increase in NCC expression 
in 3-day and 7-day induced rats was found by densitometry.  
 
As activity of NCC largely depends on phosphorylation (San-Cristobal et al., 2009), 
whole kidney extract from non-induced, 1-day induced, 3-day induced and 7-day 
induced groups were probed with an antibody specific for phosphorylated NCC (gift 
from Professor Dario Alessi, University of Dundee). This identified a band of 130 
kDa but no difference in phosphorylated NCC was observed following transgene 



































Figure 4-9: Whole kidney NCC protein abundance in Non Induced (NI, n=6), 1day Induced (1D, n=6), 3day 
Induced (3D, n=6) and 7day Induced (7D, n=6). Western blot analysis identified a single protein at 
approximately 130 kDa (A). Summary of densitometry quantification of 4 groups of rat is shown in B. Results 
were adjusted to GAPDH and expressed as relative density (AU= arbitrary units). Abundance of phosphorylated 
NCC in the whole kidney extract from 4 different groups of rat (C). L indicates molecular Ladder. 













4.2.4 Expression of αENaC 
 
Figure 4-10 shows a representative immunoblot and densitometry quantitation for 
αENaC in whole kidney of non-induced, 1-day induced, 3-day induced and 7-day 
induced mRen2.F rats.  Two distinct bands at the size of 35 kDa and 25 kDa were 
identified by the anti-αENaC antibody. There was a tendency for increased 
expression of ENaC after transgene induction. However this trend was statistically 
significant only for 1-day induced group. This indicates that there was a transient 
increase in αENaC expression at the early period of induction. This trend was not 
observed after either 3 or 7 days of induction.  
 
4.2.5 Expression of Sgk1 
 
Along with ENaC and NCC, the expression of Serum glucocorticoid-inducible kinase 
(Sgk1) was also measured for its important role in the regulation of epithelial sodium 
ion transport. A representative immunoblot and summary of densitometry 
quantitation of the whole kidney Sgk1 of non-induced, 1-day induced, 3-day induced 
and 7-day induced group is shown in Figure 4-11. The anti Sgk1 antibody identified 
two distinct proteins at approximately 50 kDa and 30 kDa respectively. Western blot 















































Figure 4-10: Whole kidney αENaC protein abundance in Non Induced (NI, n=6), 1day Induced (1D, n=6), 
3day Induced (3D, n=6) and 7day Induced (7D, n=6). Western blot analysis identified two distinct proteins at 
approximately 35 and 25 kDa (A). Summary of densitometry quantification of αENaC (35 kDa) from 4 groups 



































4.2.6 Expression of Nedd-4 
 
The abundance of Nedd-4 was also measured by Western blot analysis for its major 
role in ENaC activity. The apical targeting of ENaC is controlled by the ubiquitin 




Figure 4-11: Whole kidney Sgk1 protein abundance in Non Induced (NI, n=6), 1day Induced (1D, n=6), 
3day Induced (3D, n=6) and 7day Induced (7D, n=6). Western blot analysis identified two distinct 
proteins at approximately 50 and 30 kDa (A). Summary of densitometry quantification of Sgk1 (50 kDa) 
from 4 groups of rat is shown in B. Results were adjusted to GAPDH and expressed as relative density 







ligase, Nedd-4. Figure 4-12 shows the representative blot and a summary of density 
quantification of whole kidney Nedd-4 from non-induced, 1-day induced, 3-day 
induced and 7-day induced groups. Two distinct bands at approximately 60 kDa and 
55 kDa were identified by anti Nedd-4 antibody. A tendency of higher expression of 





























































Figure 4-12: Whole kidney Nedd-4 protein abundance in Non Induced (NI, n=6), 1day Induced (1D, n=6), 
3day Induced (3D, n=6) and 7day Induced (7D, n=6). Western blot analysis identified two distinct 
proteins at approximately 60 and 55 kDa (A). Summary of densitometry quantification of Nedd-4  (55 
kDa) from 4 groups of rat is shown in B. Results were adjusted to GAPDH and expressed as relative 







4.3 Effect of chronic inhibition of NCC 
 
It has been shown previously that NCC-mediated sodium transport was significantly 
enhanced following the transgene induction for 3 days and 7 days. To assess the role 
of NCC in the development in hypertension in this ANG ΙΙ-dependent model, NCC 
was chronically blocked with thiazide administration by minipump; subsequently 
induction was carried out for three consecutive days. For control purposes, a group 
of transgenic rats were used in which vehicle-carrying minipumps were implanted 
prior to the 3 days of induction.  
 
4.3.1 Effect on blood pressure 
 
Daily SBP was measured by tail cuff plethysmography before minipump 
implantation, after minipump implantation and during the period of induction. Figure 
4-13A shows that thiazide caused no significant change in blood pressure in the 
transgenic rats before the initiation of induction. Induction resulted in an increase in 
blood pressure however this increase was blunted in the thiazide-treated group 
relative to the 3-day induce group (4-13B). After 3 days of induction rats were 
anaesthetized for MABP measurements and analysis of renal function. MABP was 
found to be significantly reduced in the thiazide-treated 3-day induced group 
compare to both the vehicle only group and the 3-day induced group (Figure 4-13C). 
However the MABP of thiazide-treated 3-day induced group remained higher than 
that of the non-induced group. Thus chronic inhibition of NCC partially rescues the 






Figure 4-13:(A) Daily measurement of Systolic Blood Pressure by tail cuff (n=6). C1 to C3 represent the control 
period without any induction, M1 to M3 represent the time period after implantation of minipump carrying 
thiazide before induction starts. I1 to I2 represent the induction with I3C from day 1 to 2. (B) Comparison of 
Systolic Blood Pressure by tail cuff between 3-day induced group (Red line) and thiazide treated 3-day induced 
group (Green line). C1 to C3 represent the control period without any induction and I1 to I2 represent the 
induction period from day 1 to 2. (C) Mean Arterial Blood Pressure of 3-day induced (3day, n=9), 3-day induced 
vehicle group (Vehicle, n=6) and thiazide treated 3-day induced group (TH, n=6). Data are mean±SE and 
statistical comparisons were made by one way ANOVA with Tukey's post hoc analysis.  **=p<0.01 and 




4.3.2 Effect on renal haemodynamics 
 
Figure 4-14 shows the GFR, RPF and filtration fraction of the 3-day induced, vehicle 
only and thiazide treated 3-day induced groups. Thiazide treatment caused a 
significant reduction in GFR. Similarly a reduction in RPF was observed following 
thiazide administration, however this did not reach statistical significance. Filtration 
fraction also decreased following NCC blockade with thiazide but this reduction was 
not statistically significant.  
 
4.3.3 Effect on renal sodium handling 
 
Urinary sodium excretion was significantly enhanced following chronic inhibition of 
NCC (Figure 4-15). Notably, the sodium excretion in vehicle only group was 
comparable with 3-day induced group. Moreover, both ENaC and NCC mediated 
sodium reabsorption in vehicle only group were comparable with 3-day induced 
group. This confirmed that the DMSO vehicle did not have any additional effect on 
the sodium transport in this study. The natriuretic effect of amiloride was found to be 
significantly higher in thiazide treated 3-day induced group compared to vehicle only 
group and 3-day induced group. The increased sodium excretion in response to 
amiloride following chronic thiazide administration suggests a compensatory 
enhancement of ENaC-mediated sodium reabsorption. A characteristic natriuretic 
effect of acute NCC blockade was observed in the vehicle-carrying group but no 
change was observed in the thiazide treated 3-day induced group. This finding 
confirms that the dose used for chronic inhibition of NCC was sufficient to block its 






Figure 4-14: (A) GFR, (B) RPF, and (C) Filtration Fraction of 3-day induced (3day, n=9), 3-day 
induced vehicle group (Vehicle, n=6) and thiazide treated 3-day induced group (TH, n=6). Data are 
mean±SE and statistical comparisons were made by one way ANOVA with Tukey's post hoc 








Figure 4-15: (A) Urinary Sodium Excretion (B) ENaC mediated Sodium transport, and (C) NCC 
mediated Sodium transport of 3-day induced (3day, n=9), 3-day induced vehicle group (Vehicle, n=6) 
and thiazide treated 3-day induced group (TH, n=6). Data are mean±SE and statistical comparisons 









4.4 Effect of MR blockade on the development of  
ANG ΙΙ-dependent hypertension 
 
4.4.1 Urinary excretion of aldosterone in transgene induction 
 
To investigate the role of aldosterone in ANGΙΙ-dependent hypertension, daily 
urinary aldosterone levels were measured from a group of Cyp1a1-mRen2.F 
transgenic rats maintained in metabolic cages. In this study, following  three days of 
acclimatization period, control measurements were made over a further three days. 
Subsequently rats were induced by daily gastric gavage of I3C for seven consecutive 
days. Figure 4-16 shows the daily urinary aldosterone excretion for the control 
period and during the seven days of induction. The urinary aldosterone level 
remained comparable with control period during the first two days of induction. A 
significant increase was observed from the third day of induction. Moreover it had 
increased up to 15-fold by day five and remained elevated for the rest of the 
induction period. 
 
Aldosterone plays a key role in the regulation of distal nephron sodium reabsorption. 
An elevated plasma level of aldosterone was reported earlier in this transgenic rat 
model following induction. The current study has shown that urinary aldosterone 
levels increased up to 15-fold following 5 days of induction. This excessive 
formation of aldosterone may stimulate distal nephron sodium reabsorption and as a 
result reduce the excretion of sodium. Aldosterone stimulates the reabsorption of 
sodium via activation of its receptor. Thus it was hypothesized that chronic blockade 
 
of MR would increase the urinary excretion of sodium and as a consequence 
abrogate the hypertensive phenotype. To investigate whether the observed alteration 
in renal sodium retention was mediated by aldosterone, MR was chronically blocked 
with spironolactone, administrated by minipump, subsequently induction was carried 











Figure 4-16: Daily measurement of urinary aldosterone excretion during control period 
and transgene induction. C1, C2 and C3 represent the control period without any 
induction. I1 to I7 represent the induction from day 1 to 7. Data are mean±SE and 
statistical comparisons were made by repeated measures ANOVA with Tukey's post hoc 
analysis. *=p<0.05, **=p<0.01 and ***=p<0.001 vs mean of control period readings.  
Urinary Excretion of Aldosterone 
*** *** * ** 
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4.4.2 Effect on blood pressure 
 
To assess the effect of MR blockade on the development of hypertension daily SBP 
was measured before minipump implantation, after minipump implantation and also 
during the induction. Figure 4-17 shows that MR blockade had no significant effect 
on blood pressure in non-induced transgenic rats. Induction resulted in an increase in 
blood pressure. At the end of the 3 days of induction regime, rats were anaesthetized 
for MABP measurement and analysis of renal function. MABP of the 3-day induced 
MR antagonist treated group was significantly elevated compare to non-induced 
control group and this was comparable with MABP of 3-day induced group (Figure 
4-18A). These data indicate that MR blockade failed to rescue the hypertensive 
phenotype. 
 
4.4.3 Effect on renal haemodynamics 
 
Figure 4-18 shows the GFR and RPF of non-induced, 3-day induced and MR 
blockade 3-day induced groups. Both GFR and RPF of MR blockade 3-day induced 
group were comparable with non-induced control however they were significant 
reduced relative to 3-day induced group. Therefore MR blockade could not rescue 


























Figure 4-17: (A) Daily measurement of Systolic Blood Pressure by tail cuff 
plethysmography (N=6). C1 and C3 represent the control period without any induction. M1 
to M3 represent the SBP after minipump implantation and before any induction. I1 to I3 
represent the induction from day 1 to 3. Data are mean±SE and statistical comparisons were 
made by repeated measures ANOVA with Tukey's post hoc analysis. **=p<0.01 and 
***=p<0.001 vs mean of control period readings. 
Daily Measurement of SBP 








Figure 4-18:  (A) MABP, (B) GFR, and (C) RPF of non-induced (NI n=8) 3-day induced (3day, 
n=9),  and MR blockade 3-day induced  (Spiro, n=6) group. Data are mean±SE and statistical 
comparisons were made by one way ANOVA with Tukey's post hoc analysis. *=p<0.05, 





4.4.4 Effect on renal sodium handling 
 
Urinary excretion of sodium, ENaC mediated sodium transport and NCC mediated 
sodium transport from non-induced, 3-day induced and MR blockade 3-day induced 
groups are summarised in Figure 4-19. MR blockade had no significant effect on 
urinary sodium excretion, with values in the MR blockade 3-day induced group 
being similar to those of the 3-day induced group. However urinary excretion of 
sodium was significantly lower in the MR blockade 3-day induced group than in the 
non-induced group. Moreover MR blockade did not have any effect on sodium 
retention mediated by either ENaC or NCC.  
 
4.4.5 Effect on urinary albumin excretion 
 
Figure  4-20 shows the urinary albumin excretion of non-induced, 3-day induced and 
MR blockaded 3-day induced groups. Urinary albumin excretion was increased 
nearly two fold following 3 days of induction. Chronic inhibition of MR by 
spironolactone significantly reduced urinary albumin excretion in non-induced rats 










Figure 4-19:  (A) Urinary Excretion of sodium, (B) ENaC mediated sodium reabsorption and (C) NCC 
mediated sodium reabsorption of non-induced (NI, n=8), 3-day induced (3day, n=9) and MR blockade 3-day 
induced  (Spiro, n=6) group. Data are mean±SE and statistical comparisons were made by one way ANOVA 





























Figure 4-20: Urinary Albumin Excretion of non-induced (NI, n=8), 3-day induced (3day, n=9) and MR 
blockade 3-day induced (Spiro, n=6) group. Data are mean±SE and statistical comparisons were made by 
one way ANOVA with Tukey's post hoc analysis.  **=p<0.01 and ***=p<0.001 vs NI group. 
 
4.5 Effect of AT1 receptor blockade on the 
development of ANGΙΙ-dependent hypertension 
 
At the cellular level, the action of ANGII is mediated by two G protein coupled 
receptors, AT1 and AT2. ANGΙΙ exerts most of its physiological actions through the 
AT1 receptor. Although it has not been measured in the current study, several studies 
have shown that both plasma and renal ANG ΙΙ levels were increased in the Cyp1a1-
mRen2.F transgenic rat following induction (Kantachuvesiri et al., 2001, Mitchel et 
al., 2006). Chronic administration of an AT1 receptor antagonist prevented the 
hypertensive phenotype in Cyp1a1-mRen2.F transgenic rats induced with I3C 
(Mitchel et al., 2006, Vanourkova et al., 2006). The main objective of the present 
study was to investigate the role of ANGΙΙ in the development of Cyp1a1-mRen2 
transgene induced hypertension. Additionally its role in the altered renal sodium 
handling was assessed.  AT1 receptors were blocked prior to and during induction by 
administration of losartan in the drinking water. 
 
4.5.1 Effect on blood pressure 
 
To assess the role of ANGΙΙ in the development of hypertension, daily SBP was 
measured by tail cuff plethysmography during the experimental regime (for detail 
see Figure 2.5). Figure 4-21A shows that AT1 receptor blockade had no effect on 
blood pressure before induction of transgenic rats. Induction resulted in a significant 
increase in blood pressure. However, as shown in figure 4-21B the increase was 
blunted in the losartan treated 3-day induced group compared to 3-day induced 
group. On day 3 of induction rats were anaesthetized for MABP measurement and 
 
analysis of renal function. Losartan significantly reduced the MABP relative to the 3-
day induced group (Figure 4-22A). However blood pressure in losartan treated 3-day 
induced group was still significantly higher than that of non-induced group. This 




Figure 4-21: (A) Daily measurement of Systolic Blood Pressure by tail cuff plethysmography (n=6). C1 to C3 
represent the control period, L1 to L3 represent the time period when AT1 receptor was blocked by losartan before 
any induction. I1 to I3 represent the induction period from day 1 to 3 when AT1 receptor was blocked by losartan. 
Data are mean±SE and statistical comparisons were made by repeated measures ANOVA with Tukey's post hoc 
analysis. *=p<0.05 and ***=p<0.001  vs mean of control period readings.  
(B) Comparison of Systolic Blood Pressure by tail cuff plethysmography between 3-day induced group (green line) 
and AT1 receptor blocked 3-day induced group (Red line). C1 to C3 represent the control period without any 
induction and I1 to I3 represent the induction period from day 1 to 3. Data are mean±SE and statistical 
comparisons were made by two way ANOVA with Tukey's post hoc analysis. **=p<0.01 and ***=p<0.001.  
*** *** * 
 
4.5.2 Effect on renal haemodynamics 
 
 Figure 4-22 shows the GFR and RPF of non-induced, 3-day induced and AT1 
receptor blockade 3-day induced group. The GFR of AT1 receptor blocked 3-day 
induced group was comparable with non-induced control group. Moreover it was 
significantly reduced compared to the 3-day induced rats. Thus transgene induced 
elevation of GFR was normalized by AT1 receptor blockade. However no significant 
change in RPF was observed due to AT1 receptor blockade. 
 
4.5.3 Effect on renal sodium handling 
 
Urinary excretion of sodium, ENaC mediated sodium transportation and NCC 
mediated sodium transportation from non-induced, 3-day induced and AT1 receptor 
blockade 3-day induced group are summarised in Figure 4-23.  As shown in figure 4-
23A, AT1 receptor blockade prevented the increased sodium reabsorption that 
occurred following 3 days of induction. ENaC mediated sodium reabsorption was not 
different between the groups (Figure 4-23.B). However AT1 receptor blockade 
prevented the activation of NCC mediated by Cyp1a1-mRen2 transgene induction 









Figure 4-22:  (A) MABP, (B) GFR, and (C) RPF of non-induced (NI, n=8) 3-day induced (3day, 
n=9), and AT1 receptor blocked 3-day induced (3day+Losa, n=6) group. Data are mean±SE and 
statistical comparisons were made by one way ANOVA with Tukey's post hoc analysis. *=p<0.05 











Figure 4-23: (A) Urinary Excretion of Sodium, (B) ENaC mediated Sodium reabsorption, and (C) NCC 
mediated Sdoium reabsorption of non-induced (NI, n=8) 3-day induced (3day, n=9), and AT1 receptor 
blocked 3-day induced (3day+Losa, n=6) group. Data are mean±SE and statistical comparisons were 




















Hypertension is an important public health challenge as it is a major risk factor for 
cardiovascular and renal morbidity and mortality (Whelton, 1994). Worldwide, more 
than 7 million deaths are caused by hypertension every year and approximately one 
in four adults are affected by hypertension or its consequences (Kearney, 2005). 
Better management of hypertension can reduce the prevalence of cardiovascular 
disease but with the current poor hypertension control rates worldwide, more 
individuals are being referred for resistant or refractory hypertension (Chobanian, 
2009). It is likely that the treatment of hypertension would be improved with a better 
understanding of the underlying causes. It is well known that activation of the renin–
angiotensin system occurs in a significant proportion of hypertensive patients 
hypertension and predisposes patients to progressive chronic kidney disease. Even in 
patients with essential hypertension who have no obvious signs of RAAS activation, 
drugs that target the system can be therapeutically effective.  Experimentally, several 
approaches have documented the critical role of angiotensin II, the active component 
of the RAAS, in the development of hypertension. It is well established, for example, 
that chronic administration of sub-pressor doses of angiotensin II cause a slowly 
developing increase in arterial blood pressure (Simon et al., 1995) in both man and 
experimental animals. In the Goldblatt model of renal vascular hypertension, 
excessive production of renin drives the production of angiotensin II which in turn 
causes the development of hypertension. Each of these models displays altered renal 
function (Navar et al., 1998, Wang et al., 2000) and a sensitivity of blood pressure to 
dietary salt has also been reported (Ando et al., 1990). More recently, cross 
 
transplantation studies were used to identify altered renal function as a key 
component of angiotensin II-dependent hypertension (Crowley et al., 2006). 
In the current thesis, the Cyp1a1-mRen2.F transgenic rat was used to model ANG ΙΙ-
dependent hypertension. In this model, the production of renin by the mouse Ren2 
transgene causes activation of the RAAS and an increase in blood pressure. 
Transcription of the mRen2 transgene is controlled by the inducible Cyp1a1 
promoter: in the current experiments an induction protocol was used that typically 
drives the hypertension from a stable, “essential” status to a malignant phase within 
7-10 days (Liu et al., 2009). It was hypothesized that abnormal renal function 
contributed to the development of hypertension and to the transition from the 
essential to malignant phase. It was found that the hypertension was sodium-
dependent and associated with the enhanced tubular sodium reabsorption. The effect 
was localized to the distal nephron, specifically to AT1 receptor-mediated activation 
of NCC. 
 
5.1 Hypertension develops in a time-dependent manner 
 
The Cyp1a1 inducible promoter offers an experimentally tractable system for 
induction of hypertension in the Cyp1a1-mRen2 transgenic rat. In earlier studies, it 
has been shown that the transgene can be induced in a dose-dependent manner. 
Different levels of transgene induction cause different levels of hypertension with 
varying severity (Mitchell et al., 2006). In particular, a higher dose of I3C (0.3% 
w/w) by dietary supplement causes a severe hypertension within a week. Conversely 
a lower dose of I3C (0.15% w/w) for 2 weeks induces a slow developing mild 
 
hypertension which is comparable with the phenotypes of ANG II-infused 
hypertensive rats, 2K1C Goldblatt hypertensive rats and TGR(mRen2)27 transgenic 
rats (Von Thun et al., 1994; Guan et al 1992; Zou et al., 1998; Mitchell et al., 1997). 
 
The current study demonstrated that induction of Cyp1a1-mRen2.F transgenic rats 
with I3C for 1, 3 and 7-days resulted in a time-dependent increase in blood pressure. 
In non-transgenic rats, I3C did not alter blood pressure. This suggested that the 
effects of I3C on blood pressure in transgenic rats were not from the result of a non-
specific action of I3C rather due specifically to activation of the Cyp1a1-mRen2 
transgene. Indeed, transgene induction for up to 3-days resulted in a comparatively 
mild hypertension. A more severe hypertension was observed following 7-days 
induction at which point the blood pressure had increased ~70mmHg over baseline. 
Using this dosing regime, the acceleration of blood pressure occurs typically after 6-
7 days of induction (Liu et al., 2009) on the Fischer 344 background, and the 
transition from essential to malignant phase of hypertension. At this point following 
7-days of induction, characteristic manifestations of malignant hypertension in 
rodents, such as a pronounced body weight loss, polyuria, lethargy and a hunched 
posture (Whitworth et al., 1994, Whitworth et al., 1995) were observed in some of 
the rats. Thus the Cyp1a1-mRen2.F transgenic rat model allows us to induce the 
transgene expression and subsequently hypertension in a controlled manner. 
Specifically, in this study the induction of transgene at different time points 
facilitated the opportunity to study the renal changes that occurred during the 




5.2 Measurement of blood pressure in conscious and 
anaesthetized rats 
 
Accurate measurement of blood pressure is essential in the study of hypertension. 
The determined values of blood pressure, their reliability and appropriate 
interpretation are highly influenced by the method selected. Thus, a particular 
technique for measuring BP may be well suited for one type of study but less useful 
for another. In the present study the effect of transgene induction on blood pressure 
was measured using two different methods. Tail cuff plethysmography was used to 
measure blood pressure in conscious rats and in anaesthetized rats MABP was 
determined by direct cannulation of a carotid artery. Both of these methods have 
advantages and disadvantages.  
 
5.2.1 Measurement of blood pressure by tail cuff plethysmography 
 
Tail cuff plethysmography is the most commonly used indirect method for blood 
pressure measurement in animals. A variety of blood flow sensors have been devised 
for sensing the pressure at which blood flow changes during manipulation of cuff 
occlusion pressure (Kurtz et al., 2005). The main advantage of this indirect method is 
that it is noninvasive and does not require surgery. Additionally it facilitates the use 
of same animal to obtain repeated measurements of blood pressure and can be 
performed on conscious animals without the interference of anaesthetic (Krege et al., 
1995; Meneton et al., 2000; Van Vliet et al., 2000). The major drawback of the tail 
cuff method is that it requires the physical restraint of the animal. In addition the 
 
animal must be preheated to increase blood flow through the tail vein to ensure that 
tail blood flow is sufficient for measurement. The substantial amount of stress 
imposed by the restraint and preheating is known to affect BP, heart rate and stress 
hormones (Bunag & Butterfield, 1982; Gross & Luft, 2003; Popovic, 1988; Irvine et 
al., 1997). The restraint stress can be minimized by taking a great care to train the 
animals for at least 5-7 days prior to experiment. This period of training allows the 
animals to acclimatize to the heating chamber and restraint (Gross & Luft, 2003).  
 
In the current study animals were acclimatized for at least 5 days to minimize the 
impact of stress and to lessen motion artifacts during the measurement procedure. 
Blood pressure measurement data were taken only when a consistent blood pressure 
reading was obtained on two consecutive days. In addition to proper training, a cover 
was placed over the animals, the equipment kept free from foreign scent and urine 
odor was used to reduce stress and improve measurement reliability. However due to 
the limitation of the tail cuff method, any change observed in tail cuff blood pressure 
may not be attributed to the experimental treatments only. A portion of blood 
pressure changes may be an artifact caused by the animal’s stress. Thus in the current 
study, along with tail cuff measurement, the blood pressure was also measured by 
direct cannulation of a carotid artery.  
 
5.2.2 Direct measurement of blood pressure by cannulation 
 
Direct recording of BP using fluid-filled catheters is the oldest and most widely used 
method for the direct measurement of arterial pressure. This technique is very 
versatile and can be used effectively for acute studies in anaesthetized animals or for 
 
long-term, continuous monitoring of arterial pressure in conscious animals (Van 
Vliet et al., 2000). Long-term recording requires a special arrangement of a swivel 
and tether system, additionally care must be taken to ensure the continued patency of 
the arterial catheter. Moreover catheter implantation and surgery cause disturbance 
on blood pressure and heart rate. In the current study direct measurement of blood 
pressure by this method was only performed in acute settings. As the rats were 
induced with I3C daily by gastric gavage it was not possible to monitor blood 
pressure over the long term in a chronic setting, using indwelling carotid arterial 
cannulae. In the current study acute settings allowed us to perform renal clearance 
and blood pressure monitoring at the same time. Additionally we were able to 
examine the effect of amiloride and thiazide administration on blood pressure. The 
main disadvantage of this system is the effect of anaesthetic and surgical 
manipulation as discussed below. 
 
In the current experiment direct blood pressure was measured in terminally 
anaesthetized rats using thiobutabarbital (Inactin) anaesthetic and the following 
discussion will be limited to that class of drug. Barbiturate anaesthesia typically 
induces only a modest depression in blood pressure (Walker et al., 1983) that is 
smaller than those produced by other anaesthetic classes such as propofol (Stoelting 
& Miller, 2007). This makes barbituates an ideal choice for renal physiological 
studies: the change in blood pressure is usually within the autoregulatory range, 
consequently renal perfusion pressure is maintained at near normal levels. The 
decrease in blood pressure is mainly caused by peripheral vasodilation and depressed 
sympathetic nervous system outflow from the CNS and may be offset, to a degree, 
by a compensatory tachycardia (Walker et al., 1983). Indeed, following surgical 
 
intervention (Walker et al., 1983), blood pressure may be comparable or indeed 
higher than in conscious animals, due to enhanced CNS-mediated effects.  
5.2.3 Radio telemetry 
 
This is the most comprehensive and reliable technology to monitor blood pressure in 
conscious freely moving laboratory animals (Brockway et al., 1991; Kramer et al., 
2001). The technology has been extensively validated and is available for use in all 
laboratory animals. Implantable radiotelemetry has the advantage of direct and 
continuous measurement of BP without the need for restraint or tethering devices. 
The continuous data acquisition facility of radiotelemetry provides the opportunity to 
measure BP around the clock for extended periods of time. (Kramer et al., 2001; 
Kramer & Kinter, 2003) The main advantage of this method is the large number of 
measurements that can be obtained from a single animal, which has substantial effect 
on the precision of the estimates and the number of animals required to estimate BP 
accurately (Van Vliet et al., 2000). Blood pressure measurement using telemetry was 
beyond the scope of the current study, however, we have previously reported the 
blood pressure data following transgene induction measured using radio telemetry 
(Liu et al., 2009). 
 
5.2.4 Comparison of blood pressure recorded from conscious and 
anaesthetized rats 
 
In a previous study from our lab, blood pressure was measured in conscious Cyp1a1-
mRen2.F transgenic rats by radio telemetry (Liu et al., 2009). Prior to transgene 
induction, the baseline MABP recorded was approximately 112 mmHg and 
 
following a 7-day induction, had increased to approximately 160 mmHg; at net gain 
of ~50mmHg. In the current study, the MABP in conscious rats was measured prior 
to induction and during the induction by tail cuff plethysmography. The baseline 
MABP recorded in this way was similar to that recorded by telemetry and the rise in 
BP following a 7-day induction period was ~70mmHg. However the blood pressure 
rises recorded by tail cuff plethysmography was comparatively higher than that 
recorded with telemetry and it may be related to the stress associated with the tail 
cuff plethysmography blood pressure measurement system. Under Inactin 
anaesthesia, baseline BP was comparatively higher than that recorded in either of the 
conscious profiles but the increment following 7 days of induction was of a similar 
magnitude. This apparent pressor effect of Inactin has been reported before and may 
reflect activation of the SNS by surgical intervention (Walker et al., 1983; Vasthare 
et al., 1988). Although in the current study comparatively higher MABP was 
recorded in direct measurement of blood pressure by cannulation, we are unable to 
determine whether this was the result of stress associated with anaesthesia or 
surgery. In summary, however, the data obtained under terminal anaesthesia are 
comparable in terms of the size of the hypertensive response to data obtained in 
conscious rats. 
 
5.3 Natriuretic capacity and sodium retention  
Guyton and colleagues hypothesized that the kidney plays a central role in blood 
pressure regulation and an alteration in renal function or resetting of the pressure-
natriuresis relationship is a prerequisite for the development of hypertension 
(Guyton, 1972). Simply, pressure-natriuresis means that an elevation in perfusion 
 
pressure in the renal artery causes an increase in sodium and water excretion by the 
kidney. They further hypothesized that the substantial capacity for sodium excretion 
by the kidney provides a compensatory system of virtually infinite gain to oppose 
processes, including increases in peripheral vascular resistance, which would tend to 
increase blood pressure (Guyton, 1972; Guyton et al., 1991). Due to impairment in 
renal excretory function the relationship between renal sodium excretion and renal 
perfusion pressure is shifted chronically toward higher levels of BP and this 
impairment precedes the development of hypertension (Aperia et al., 1972). 
 
The mechanism of pressure natriuresis is multifactorial and responds differently to 
acute and chronic increases of blood pressure. When blood pressure is increased 
acutely, pressure natriuresis appears to be the result of a rapid decrease in proximal 
tubule salt and water reabsorption. It is mediated by a rapid redistribution of apical 
proximal tubule NHE3 from the microvilli to intermicrovillar clefts and then 
endosomal pools, and suppression of basolateral Na,K-ATPase activity (McDonough 
et al., 2003). In chronic settings pressure natriuresis is achieved by inhibition of 
tubular sodium transport in distal nephron and collecting duct segments as a 
consequence of changes in the activity of the ENaC and NCC (Navar & Majid, 1996; 
Navar et al., 1986). 
 
It is well established that activation of the RAS markedly suppresses the pressure-
natriuresis relationship (Hall et al., 1999; Hall et al., 1990). Several studies have 
demonstrated a rightward shift in the pressure-natriuresis relationship in different 
types of hypertension (Gross et al., 1995; Gross et al., 1997; Roman & Cowley 1985; 
 
Roman, 1986). In the rat, infusion of ANG II leads to marked impairment of sodium 
excretion and suppression of the pressure-natriuresis relationship (Wang et al., 2000; 
Van der Mark & Kline, 1994). AT1 receptor blockade prevented the suppression of 
pressure-natriuresis and the hypertension, suggesting that pressure-natriuresis 
modulation by ANG II is primarily mediated by AT1 receptor (Wang et al., 2000). 
Similarly in transgenic rats harbouring both human renin and human angiotensinogen 
genes (Dehmel et al., 1998) or transgenic rat for mouse renin gene, TGR(mRen2)27 
(Gross et al., 1994) the renal pressure-natriuresis mechanism is reset towards higher 
pressure levels and participates in the maintenance of hypertension. A marked 
attenuation in the pressure-natriuresis relationship has also been identified as a prime 
contributor for the development of hypertension in the Cyp1a1-mRen2.F transgenic 
rat model (Erbanova et al., 2009). Enhanced tubuloglomerular feedback likely 
contributes to the inability of the kidney to maintain normal rates of sodium 
excretion (Mitchell & Mullins, 2005). The pressure-natriuresis relationship is 
maintained by accurate regulation of renal haemodynamics and tubular reabsorption. 
Thus derangement of renal haemodynamics and tubular transport by ANG ΙΙ are 
responsible for altered pressure-natriuresis.  
 
The pressure natriuresis response can be measured by measuring the natriuresis 
induced by an acute pressure ramp. This was not performed in the current thesis but 
nevertheless we have indirect data suggesting impaired renal natriuretic capacity. In 
the present study it has been observed that the induction of the Cyp1a1-mRen2 
transgene did not significantly change either GFR or RPF over the experimental 
time-course. This is discussed in more detail in section 5.6 below. However this 
 
observation put forward the suggestion that enhanced tubular salt and water 
reabsorption might contribute importantly to the maintenance of the hypertensive 
phenotype. Indeed, the current study shows that urinary sodium excretion is 
markedly altered in Cyp1a1-mRen2.F rats following I3C administration in response 
to the infusion of a saline load, thus there is a blunted natriuresis compared to non-
induced rats. One possibility might be the alteration in filtration fraction by ANG ΙΙ. 
This may lead to augmentation in proximal tubular solute and fluid reabsorption 
(Kline & Liu 1994; Mattson et al., 1991; Roman et al., 1988; Roman & Kaldunski, 
1991) and thereby contribute to an inappropriately augmented tubular reabsorptive 
capability in the hypertensive rats. Another possibility might be the direct or indirect 
action of ANG ΙI to stimulate tubular sodium transport activity (Peti-Peterdi et al., 
2002; Komlosi et al., 2003; Burns & Li, 2003; Beutler et al., 2008; Barreto-Chavas 
& Mello-Aries, 1996; Wang & Giebisch, 1996). In the current study fractional 
sodium excretion was reduced in each of the experimental groups following 
induction, suggesting that the antinatriuresis was of tubular origin. However no 
change in filtration fraction was observed following transgene induction 
Furthermore, the fractional excretion of lithium, an indirect marker for the proximal 
tubule sodium reabsorption, (Thomsen et al., 1969) was elevated after 1- and 3-days 
of hypertension, indicating diminished proximal tubular reabsorption (Table 3.2; 
ANOVA P<0.001). However, there was evidence for enhanced proximal 
reabsorption in the 7-day induced group, but the CNa/CLi ratio, a marker for distal 
sodium reabsorption, was suppressed throughout the induction regimen (Table 3.2; 





5.4 Balance study 
 
The renal clearance studies clearly indicate that activation of the RAAS is associated 
with an impaired natriuretic response to a sodium load but this does not necessarily 
mean that sodium retention plays a key role in the development of the hypertension 
in this model. A metabolic cage study was therefore performed to examine sodium 
homeostasis in conscious animals both before and during the induction of the 
Cyp1a1-mRen2 transgene. We found no evidence of altered daily sodium balance 
following transgene induction from this experiment. Indeed, there was no evidence at 
all for expansion of plasma volume, even transiently, during transgene induction. In 
the current study polyuria was observed in transgenic rats but at same time there was 
a parallel increase in daily water intake and thus there was no alteration in net water 
balance. In fact there was a significant linear trend (P<0.01) for haematocrit to 
increase with increasing duration of transgene induction. Although plasma volume 
was not measured directly, using Evans blue for example (el-Sayed, 1995), increased 
haematocrit is consistent with a contraction in plasma volume, rather than volume 
expansion.  
 
It is classically established that sodium retention is followed by water retention, 
leading to volume expansion. Guyton’s hypothesis rests on the fact that this is 
transient and pressure natiruresis leads to diuresis and restoration of plasma volume 
(Guyton, 1991). However, recent data challenge this dogma, showing that substantial 
amounts of sodium could be accumulated without causing water retention via 
 
osmotically inactive sodium storage or an osmotically neutral cation exchange 
mechanism (Titze, 2009). Water-free sodium retention attenuates the blood pressure 
by maintaining the ECV close to normal even after increased sodium retention. Thus 
volume retention and the associated body weight increase do not always parallel 
sodium retention (Titze et al., 2003; Titze et al., 2004). This osmotically inactive 
sodium storage leads to hypertonicity and osmotic stress in the skin interstitium. In 
response to the osmotic stress subcutaneous tissue macrophages express the 
transcription factor tonicity enhancer binding protein and induce a local regulatory 
cascade resulting in the secretion of vascular endothelial growth factor C. 
Consequently the vascular endothelial growth factor C enhances endothelial nitric 
oxide synthase expression (Machnik et al, 2009). Thus hypertonic skin sodium 
storage provides a buffering mechanism for hypertension (Machnik et al, 2009; Titze 
& Machnik, 2010). However in the current study no evidence of sodium retention 
was found from the metabolic cage study. This might be attributed to the significant 
decrease in food intake following transgene induction and thus animals were not in 
sodium balance. It is well known that ANG ΙΙ infusion causes a hypertension that is 
salt sensitive but several studies suggest that this is not associated with significant 
sodium retention (Ballew & Fink, 2001). It is possible that hypertension followed by 
increased sodium retention is not exclusively due to volume expansion rather it 
enhances the sensitivity of the SNS (Ando et al., 1991) and VSM (Simon et al, 1998) 
to ANG ΙΙ. However in the current study there was no significant increase in plasma 
sodium concentration following transgene induction.  
 
It has been observed that hypokalaemia induces renal structural changes such as 
 
renal hypertrophy and tubulointerstitial injury (Muehrcke & Rosen, 1964, 
Riemenschneider & Bohle, 1983). In concert, hypokalaemia also causes an alteration 
in vasoactive mediators which together induce salt sensitivity hypertension (Suga et 
al., 2001). In the current study there was a linear trend toward hypokalaemia, despite 
which fractional potassium excretion remained robust suggesting a possible role of 
potassium in the pathogenesis of hypertension in this transgenic rat model. A further 
study is required to address this issue. 
 
Daily measurements of body weight during the metabolic cage study clearly 
demonstrate that the development of hypertension was accompanied by a significant 
body weight loss. Previously it has been reported that the occurrence of a severe 
form of hypertension with the higher dose of I3C is associated with pronounced body 
weight loss (Kantachuvesiri et al., 2001; Mitchell & Mullins, 2005; Opay et al., 
2006; Ortiz et al., 2007a; Patterson et al., 2007; Vanourkova et al., 2006) but this 
trend was not been observed in mild hypertension induced by the lower dose of I3C 
(Mitchell, 2006). However the rapid body weight loss is not a non-specific effect of 
I3C as non-transgenic rats did not exhibit any sign of weight loss following I3C 
administration. This body weight loss can be well explained by a decrease in daily 
food intake following induction. During the metabolic cage study the daily food 
intake was found to be decreased after 3 days of induction and this decrease resulted 
in a continuous reduction of body weight throughout the induction regime. 
Conversely, in other studies (Ortiz et al, 2007; Vanourkova et al., 2006) the food 
intake was not reduced significantly following induction. Rather, those studies 
reported the accentuated pressure diuresis or ANG II mediated increased catabolism 
of fat and/or lean tissue as the cause for loss of body weight. In the current study 
 
polyuria was observed in transgenic rats but at same time there was a parallel 
increase in daily water intake and thus there was no alteration in net water balance. 
Thus the observed polyuria can almost be accounted for by the polydipsia indicating 
that the rats are not losing bodyweight as a consequence of urinary water loss. The 
observed discrepancy in daily food intake might be attributed to the route of 
administration of I3C. In the current study I3C administration was carried out 
through gastric gavage but in other studies I3C was administrated as dietary 
supplementation. The administration of I3C by gastric gavage induced hypertension 
more rapidly compared to dietary administration which leads to a significant 
reduction in daily food intake. 
 
5.5 Sodium dependence of the hypertensive response 
 
Although increased renal sodium reabsorption was associated with the development 
of hypertension, absolute sodium retention was not found. To investigate the role of 
sodium in the development of hypertension, a study was performed in which rats 
were maintained on a diet that was essentially sodium-free before and during 
induction of the Cyp1a1-mRen2 transgene. Under dietary sodium restriction, 
transgene induction still caused a substantial increase in blood pressure over baseline 
but this was partially blunted compared to rats maintained on a normal sodium diet. 
Importantly, on a low sodium diet, no symptoms of malignant hypertension were 
observed, which might be due to the hypotensive effect of this regimen. These 
findings suggest that the development of hypertension in this model is salt 
dependent. In accordance with this observation, it has been reported that in increased 
 
ANG II levels or an impaired response of ANG II production to dietary salt change is 
associated with the salt-sensitive component of hypertension in different 
hypertensive rat models such as spontaneously hypertensive rats, ANG II-infused 
rats and TGR(mRen2)27 rats (Hodge et al., 2002; Huskova et al., 2007; Osborn et 
al., 2003; Wang et al., 2000).  
 
The Cyp1a1-mRen2.F transgenic rat model exhibits salt-dependency in the 
development of hypertension. Very recently a detailed study on the effect of dietary 
sodium on the development of hypertension in Cyp1a1-mRen2.F transgenic rats 
showed that a low salt diet containing 0.01% sodium substantially attenuated the 
development of hypertension and a high salt diet containing 8% sodium potentiated 
the course of hypertension (Husková et al., 2010). However high salt diets 
containing 2% and 4% sodium respectively did not have any incremental effect on 
the development of hypertension. It has also been reported that TGR(mRen2)27 
showed an attenuated development of hypertension when fed on low salt diet 
(Husková et al., 2007). Moreover, the pressor response to an acute dose of ANG II 
was amplified in rats receiving a higher sodium diet compared to rats that received a 
lower sodium diet, suggesting that the development of ANG II-dependent 
hypertension is salt dependent. 
 
5.6 Effect of transgene induction on renal haemodynamics 
 
In the current study the possible role of renal haemodynamics was assessed in the 
development of hypertension. Although the induction of the transgene markedly 
 
increased MABP from the first day of induction, neither GFR nor RPF were affected 
in a major way. The maintenance of GFR and RPF in a normal range despite the 
increased MABP suggests a marked elevation of preglomerular vascular resistance in 
hypertensive Cyp1a1-mRen2.F transgenic rats. Indeed, the renal vascular resistance 
was found to be elevated after 7 days of induction. It has been reported that the direct 
action of ANG ΙΙ on the preglomerular vasculature or the autoregulatory response 
allows maintenance of normal renal haemodynamic function despite elevated blood 
pressure (Baber et al., 2003; Mitchell & Navar, 1988; Mitchell & Navar, 1995). 
However several studies have reported a marked suppression of renal 
haemodynamics following transgene induction in the transgenic rat model (Mitchell 
& Mullins, 2005; Mitchel et al., 2006). Conversely there is also evidence that renal 
haemodynamics remained unchanged following induction (Opay et al., 2006; 
Patterson et al., 2005). Furthermore, it has been shown that COX-2-derived 
vasodilatory metabolites play an important role in the maintenance of renal 
haemodynamics (Opay et al., 2006) and reduced bioactivity of nitric oxide due to 
increased superoxide contributes to the elevation of renal vascular resistance 
(Patterson et al., 2005). Regardless of the mechanism the current study showed that 
hypertensive Cyp1a1-mRen2.F rats exhibit markedly increased RVR and the pre-
glomerular vasculature prevents the transmission of the systemic hypertension to the 
glomerular capillaries at least up to 7 days of induction.  
 
5.7 Mechanism of enhanced sodium reabsorption 
 
Although the bulk of the glomerular filtrate is reabsorbed in the proximal tubule, 
sodium reabsorption in the distal nephron segment is responsible for fine-tuning of 
 
sodium excretion (Peti-Peterdi et al., 2002; Mullins et al., 2006). Several studies 
have demonstrated the modulatory role of ANG II on distal tubular sodium 
reabsorption     (Beutler et al., 2003, Navar et al., 2006; Peti-Peterdi et al., 2002; 
Sandberg et al., 2007; Wang & Giebisch, 1996; Wang et al., 2003). In the distal 
nephron ANG II directly stimulates the Na+/H+ exchanger, NaCl cotransporter 
(NCC) and amiloride-sensitive sodium channel (ENaC). In particular ANG II 
enhances sodium reabsorption by stimulating Na+/H+ exchanger and the amiloride-
sensitive sodium channel (ENaC) in the distal tubule and cortical collecting duct 
(Barreto-Chaves et al., 1996; Schlatter et al., 1995; Wang and Giebisch, 1996). It has 
been shown that ANG II directly increases ENaC activity in isolated perfused rabbit 
cortical collecting ducts (Peti-Peterdi et al., 2002). In AT1a receptor knockout mice, a 
marked decrease in NCC and αENaC subunit have been reported in response to 
activated RAAS. This suggests an AT1 receptor mediated regulatory role of ANG II 
to these transporter and hence sodium handling (Brooks et al., 2002).  
 
In addition to direct effects, ANG II also regulates indirectly the function of distal 
tubular sodium reabsorption:  ANG II stimulates the zona glomerulosa of the adrenal 
cortex to produce the sodium-retaining hormone, aldosterone, which enhances 
sodium transport in the cortical collecting duct and distal convoluted tubule. This 
enhancement is mainly mediated via an effect on ENaC. Aldosterone increases the 
number of functional ENaC on the cell surface and also increases the channel open 
probability (Garty & Palmer, 1997). Moreover aldosterone also regulates sodium 
reabsorption in the distal convoluted tubule by regulating NCC expression. 
Aldosterone infusion in adrenalectomized rats increased the abundance of NCC 
 
expression. Conversely spironolactone administration in salt restricted rats decreased 
the abundance of NCC (Neilsen et al., 2002).  
In the current study, the mechanisms responsible for the observed enhancement of 
renal sodium reabsorption in the distal tubule were measured using acutely 
administered blockers of ENaC and NCC. Our data indicate that increased NCC 
activity is responsible for the enhanced renal sodium retention as ENaC mediated 
sodium reabsorption was largely unchanged during Cyp1a1-mRen2 transgene 
induction. Data from the current study clearly show a progressive stimulation of 
NCC mediated sodium reabsorption during transgene induction. After 7-days of 
induction the NCC activity was approximately two-fold increased. The increased 
activity of NCC following induction was also supported by the Western blot 
analysis. An increase in total kidney NCC abundance was observed due to transgene 
induction. 
 
To further investigate the role of NCC mediated sodium reabsorption in the 
development of ANG ΙΙ dependent hypertension, NCC was chronically inhibited 
before and during transgene induction. The chronic inhibition of NCC during 
transgene induction significantly blunted the hypertensive phenotype but did not 
prevent it completely. These data suggest that increased sodium retention mediated 
by NCC plays a key role in the development of ANG II-dependent hypertension in 
this transgenic rat model. 
 
The importance of NCC in the regulation blood pressure has been widely studied. 
Gene mutation or alteration in the expression of NCC leads to an alteration in blood 
pressure. Loss-of-function mutations of NCC have been linked to Gitelman’s 
 
syndrome, which is characterized by salt wasting, mild hypotension, hypokalaemia, 
and secondary hyperaldosteronism (Cruze et al.,2001; Melander et al., 2000). 
Conversely Gordon’s syndrome, another autosomal dominant disorder linked to the 
increased activity of NCC, which is characterized by hypertension and 
hyperkalaemia. (Yang et al., 2005). Recently it has been shown that acute 
hypertension provoked the redistribution of NCC from apical to sub-apical 
cytoplasmic vesicles. However this redistribution is secondary to a reduction in ANG 
II accompanied by hypertension since clamping of ANG II to a non-pressor level 
prevented the NCC redistribution (Lee et al., 2009). These data suggest the important 
role of NCC in the regulation of sodium excretion.  
 
5.8 Activation of NCC by phosphorylation 
 
In the current study a transient increase in the abundance of NCC was observed 
following induction. However it is well established that NCC mediated sodium 
retention could also be regulated by changing the number or activity of NCC in the 
apical membrane. It has been shown that apical abundance of NCC can be regulated 
by ANG II directly and also indirectly by aldosterone (Sandberg et al., 2006, 
Sandberg et al., 2007). Acute trafficking of NCC from the sub-apical membrane to 
the apical plasma membrane was observed following ANG II infusion (Sandberg et 
al., 2007). Conversely, the ACE inhibitor captopril reversed the trafficking 
(Sandberg et al., 2007). ANG II signaling increases NCC activity by abrogating the 
inhibitory effect of WNK4. This elimination of WNK4 mediated inhibition lead to 
enhanced phosphorylation of NCC by SPAK/ORS kinases. This phosphorylation 
 
enhanced the trafficking of NCC to the plasma membrane and increased its activity 
(San-Cristobal et al., 2009). Specifically, phosphorylation of two threonine residues 
T53 and T58 is crucial for NCC activity (Richardson et al., 2008). 
 
Based on these data it was hypothesized that not only total protein expression but 
also enhanced phosphorylation and the subsequent increased apical expression might 
be responsible for activity. To address this issue, the effect of transgene induction on 
phosphorylation of the key residue was also analyzed using an antibody specific for 
phosphorylation at T53 of NCC. However no difference in phosphorylation was 
observed.  Based on this finding we cannot rule out that there was no increase in 
phophorylation of NCC.  SPAK and OSR1 phosphorylate and activate SLC12 family 
ion co-transporters that includes NCC, NKCC1 and NKCC2 (Vitari et al., 2006). 
Evidence suggests that SPAK and OSR1 directly phosphorylate several threonine 
residues in a conserved motif R-F-X-[VI] of these co-transporters (Richardson et al., 
2008). Thus the phospho-antibody not only binds specifically with phosphorylated 
NCC but also binds with phosphorylated NKCC1 and NKCC2 (personal 
communication with Professor Dario Alessi, University of Dundee). A further co-
immunoprecipitation experiment is required to address this problem. 
 
5.9 Role of ENaC in the development of hypertension 
 
There is ample evidence that ENaC mediated sodium retention plays a major role in 
salt and water homeostasis in the body and blood pressure regulation (Rossier et al., 
2002; Garty & Palmer, 1997). Genetically occurring ENaC mutations which lead to 
 
increased or decreased ENaC activity, such as Liddle’s syndrome (Liddle et al., 
1963) and type I pseudohypoaldosteronism (PHA-I) (Chang et al., 1996) also imply 
its physiological importance in blood pressure regulation. However, in the current 
study pharmacological intervention of ENaC by amiloride did not find any 
contribution of ENaC mediated sodium transport to the development of hypertension 
in this model. One possible explanation may be the increased sodium reabsorption 
along the DCT by the over activation of the upstream sodium transporter NCC, 
which may limit the Na+ load that reaches ENaC. Consistent with this explanation, 
enhanced ENaC mediated sodium reabsorption was observed when NCC was 
blocked chronically. Further study is necessary to address this possibility.  
 
5.9.1 Western blot analysis for ENaC 
 
ENaC is a hetero-oligomer consisting of three subunits α, β and γ. Among the three 
subunits, the α-subunit is rate limiting for assembly of mature ENaC complexes 
essential for normal function of the channel (Beutler et al., 2003; May et al., 1997). 
In the current study the expression of the αENaC subunit was measured by Western 
blot analysis. A transient increase in abundance of αENaC expression was only 
found following 1 day of induction and this enhancement was not sustained after 
either 3-day or 7-day induction. Thus Western blot analysis supports the findings 
from pharmacological intervention of ENaC by amiloride that ENaC mediated 
sodium reabsorption do not play any contributory role in enhanced sodium retention. 
However the activity of ENaC does not only depend on the total expression, so based 
on Western blot analysis alone we cannot rule out the possible contributory role of 
 
ENaC in the development hypertension in this model. Rather there might be an 
alteration in ENaC trafficking to the apical plasma membrane, ubiquitination, 
phosphorylation or proteolytic processing which may increase the activity of ENaC 
without increasing total expression (Bhalla & Hallows, 2008). It has been reported in 
several studies that activity of ENaC is largely regulated by the kinase SGK1 (Chen 
et al., 1999, Pearce et al., 2003) and ubiquitin protein Nedd4-2 (Snyder et al., 2002). 
SGK1 stimulates ENaC activity by direct phosphorylation of a serine residue. It also 
regulates ENaC through the phosphorylation of the ubiquitin protein Nedd4-2. SGK1 
mediated phosphorylation inhibits the binding affinity of Nedd4-2 to the target 
protein and thus reduces the ubiquitination of ENaC. This causes an increase the 
abundance of ENaC channel protein in the cell membrane. (Alvarez-de-la-Rosa et 
al., 1999; Debonneville et al., 2001). Due to the pivotal role of Nedd4-2 and SGK1 
in the regulation of ENaC activity, the abundance the SGK1 and Nedd4-2 was also 
measured in the current study. However no difference was observed in the total 
expression. It might be possible that inactivation of Nedd4-2 by SGK1 mediated 
phosphorylation regulates ENaC activity rather than by a decreas in Nedd4-2 total 
expression. Again phosphorylation is essential for SGK1 to become functional 
(Biondi et al., 2001; Kobayashi et al., 1999). This suggests that a further study is 
required to analyse the phosphorylation of ENaC and the upstream proteins 
necessary for its regulation. It would be also interesting to study the effect of 
induction on trafficking of ENaC from sub-apical space to apical membrane since 





5.10 Role of AT1 receptor activation in the development of 
hypertension 
 
It is well known that inappropriate activation of the RAS plays a major role in the 
pathogenesis of ANG II -dependent hypertension and ANG II confers most of its 
action upon binding with AT1 receptors. In the current study, the AT1 receptor 
blocker losartan had no effect on blood pressure in non-induced rats but significantly 
attenuated the hypertensive response to transgene induction. This finding suggests 
that the enhanced generation ANG II following the induction of the Cyp1a1-Ren2 
transgene causes hypertension in Cyp1a1-Ren2 transgenic rats as a consequence of 
AT1 receptor activation. This result confirms the previous finding that treatment with 
an AT1 receptor antagonist prevented the development of hypertension in this model 
(Mitchell et al., 2006, Vanourková et al., 2006). However a recent study found no 
effect of chronic administration of AT1 receptor blockade on systolic blood pressure 
in this model (Williams et al., 2010). Chronic AT1 receptor blockade also attenuates 
the development of hypertension in different ANG II -dependent hypertensive rat 
models such as 2K1C Goldblatt hypertensive rats (Imamura et al., 1995), ANG II-
infused rats (Zou et al., 1996) and TGR(mREN2)27 transgenic rats (Bohm et al., 
1995). Increased circulating ANG II as a consequence of transgene induction and the 
augmented intrarenal ANG II lead to the pathogenesis of hypertension in Cyp1a1-





In AT1a receptor knockout mice fed on low-salt diet, NCC protein abundance was 
reported to be reduced compared with wild-type mice (Brooks et al., 2002); this 
implies that NCC expression is regulated directly by ANG II stimulation. A detailed 
study from Sandberg et al. (Sandberg et al., 2007) demonstrated the direct role of 
ANG II in the trafficking of NCC to the apical membrane. Moreover ACE inhibition 
causes rapid internalization of NCC and thus suppresses NaCl reabsorption in the 
distal convoluted tubule. Although the collecting duct is the primary site for 
aldosterone action, aldosterone administration also increased the expression of NCC 
in the distal convoluted tubule (Kim et al., 1998). NCC abundance is increased 
during dietary NaCl restriction (Masilamani et al., 2002) and decreased during a 
high-salt diet (Sandberg et al., 2006; Song et al., 2004,) and mineralocorticoid 
blockade (Nielsen et al., 2002). Thus ANG ΙΙ can directly regulate NCC activity via 
AT1 receptor activation and also by increased aldosterone synthesis. 
 
In the current study AT1 receptor inhibition completely normalized the enhanced 
sodium reabsorption that was observed following transgene induction. In particular 
losartan therapy completely blunted the enhanced NCC mediated sodium 
reabsorption. This finding suugests that AT1 receptor activation by ANG II generated 
from the induction of the Cyp1a1-mRen2.F transgene is essential for increased NCC 
activity. In the current study it has already been shown that chronic inhibition of 
NCC by thiazide completely blocks the NCC activity but only partially attenuates the 
hypertensive phenotype. Again losartan completely attenuates NCC stimulation, but 
 
only partially blocks hypertension. Thus NCC is important but it is not the only 
hypertensive mechanism. 
5.11 Role of aldosterone in the development of hypertension  
 
It has previously shown that activation of the Cyp1a1-mRen2.F transgene causes a 
rapid and sustained increase in circulating ANG II concentration. Urinary 
aldosterone, used as a surrogate for plasma concentration, was found to be increased 
following induction in the current study and remained sustained throughout the 
experimental regime. The beneficial effects of losartan, described above, could be 
attributed to indirect inhibition of aldosterone synthesis. Thus, the contribution of 
increased aldosterone synthesis in the development of hypertension and its role on 
tubular sodium reabsorption was assessed. Chronic inhibition of MR by 
spironolactone did not affect the blood pressure in non-induced rats and was not able 
to prevent the hypertensive response to transgene induction. This suggests that 
aldosterone does not play a substantial role in the elevation of blood pressure in 
Cyp1a1-Ren2.F rats. Several studies have reported that increased aldosterone levels 
do not contribute significantly to the development of ANG II-dependent forms of 
hypertension (Kanagy et al., 1990; Martinez et al., 2002; Ortiz et al., 2007; Rocha et 
al., 2000; Rocha et al., 2002; Sander et al., 1992). 
 
It has been reported that chronic MR antagonism potentiates AT1 receptor-mediated 
intrarenal uptake of ANG II. This enhanced intrarenal ANG II may overcome the 
effect of MR blockade and thus maintain the sustained sodium reabsorption and 
hypertension (Nielsen et al., 2002; Nielsen et al., 2007). Alternatively spironolactone 
 
treatment may exert a positive feedback on aldosterone synthesis leading to a further 
elevation of plasma aldosterone. The elevated aldosterone level might overcome 
receptor blockade or exerts its effect through the unblocked glucocorticoid receptor 
(Gaeggeler et al., 2005; Ortiz et al., 2007b). However MR receptor blockade did not 
alter either intrarenal ANG II or plasma aldosterone levels in hypertensive Cyp1a1-
mRen2.F transgenic rats (Ortiz et al., 2007a). 
 
Although in the current study MR blockade failed to alleviate the hypertensive 
phenotype, it completely prevented the development of microalbuminuria associated 
with hypertension, suggesting that aldosterone does contribute to the renal damage in 
Cyp1a1-Ren2.F hypertensive rats but via a mechanism independent of blood 
pressure. It has been reported that aldosterone induces the production of growth 
factor by TGF-β signaling pathways which upregulates collagen synthesis, 
downregulates the release of the extracellular matrix metalloproteinase collagenase, 
and promotes fibroblast proliferation (Sun et al, 2000). Furthermore, aldosterone 
induces production of reactive oxygen species and expression of inflammatory 
molecules (Nishiyama et al., 2004) and inhibits matrix degradation by enhancing 
plasminogen activator inhibitor-1 (PAI-1) expression (Brown et al., 2000; Ma et al., 
2006). All of these contribute to the final common pathway of renal fibrosis and 
cause renal damage. Renal injury has been reported in a variety of hypertensive 
models, including spontaneously hypertensive rats (SHR), ANG II-infused 
hypertensive rats, Dahl salt-sensitive rats, DOCA-salt hypertensive rats and 
TGR[mREN2]27 transgenic rat (Bledsoe et al., 2006; Cheng et al., 2003; Rodríguez-
Iturbe et al., 2004). It is well known that selective blockade of aldosterone reduces 
 
proteinuria and nephrosclerosis independent of effects on blood pressure (Epstein et 
al., 2001). In the malignant hypertensive Cyp1a1-mRen2.F transgenic rat model, 
renal pathological changes primarily consist of inflammation and cellular 
proliferation in the cortical vessels and tubulointerstitium (Graciano et al., 2007) and 
it has been shown that chronic treatment with spironolactone completely alleviated 
the proteinuria associated with renal injury.  
 
In the current study it has been shown that MR blockade had no significant effect on 
urinary sodium excretion. Furthermore, MR blockade did not have any effect on 
sodium retention mediated by NCC. It is well known that aldosterone directly 
regulates distal tubular sodium transport. However the present findings suggest that 
AT1 receptor activation by ANG II play a key role in the regulation of NCC activity 
and this activation can mask the MR blockade effect. However, further study is 
















In summary, the present findings demonstrate that induction of the Cyp1a1-mRen2 
transgene caused a progressive increase in blood pressure in a time dependent 
manner and this development of angiotensin II-dependent hypertension is mediated 
by increased tubular sodium reabsorption rather than altered renal blood flow. The 
enhanced sodium reabsorption in the distal nephron specifically the increased 
activity of the thiazide-sensitive sodium chloride cotransporter (NCC), is a key 
hypertensive mechanism in this model. Increased activity of NCC results directly 
from the actions of ANG II mediated through AT1 receptor activation. Evidence has 
been presented in the current study that places NCC in a central position for the 
development of hypertension in the Cyp1a1-mRen2 transgenic rat. Chronic 
administration of either hydrochlorothiazide or the AT1 receptor antagonist losartan 
completely blocked NCC activity and normalized distal tubule sodium reabsorption 
but only partially attenuated the hypertensive phenotype. Similarly dietary sodium 
restriction also blunted the hypertensive phenotype partially. These suggest that NCC 
mediated enhanced sodium reabsorption is important but is not the only hypertensive 
mechanism in this model. Finally the present study suggests that aldosterone does 
not contribute to the development of either hypertension or increased NCC activity 








The relationship between dietary sodium and the pathogenesis of essential 
hypertension has been an area of interest and investigation for decades. About 51% 
of the hypertensive population and 26% of normotensive individuals are salt sensitive 
(Weinberger, 1996). It has been reported that the prevalence of hypertension is more 
frequent in salt-sensitive individuals compare to their salt-resistant counterparts 
(Weinberger & Fineberg, 1991). Furthermore, the incidence of cardiovascular events 
is 3 fold higher in salt-sensitive hypertensive patients (Moromoto, 1997) and salt-
sensitive normotensive individuals have increased mortality independent of blood 
pressure (Weinberger et al., 2001). Transient activation of the RAAS can cause salt-
sensitivity to develop which in itself is an important risk factor for cardiovascular 
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